Vaccines and Global Health: The Week in Review
21 May 2022 :: Issue 658
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
Seventy-fifth World Health Assembly  WHA 75
22-28 May 2022

Selected Agenda Documentation
A75/GC/1 Rev.1 Preliminary daily timetable for the Seventy-fifth World Health Assembly

A75/1 Rev.1
Provisional agenda

A75/5
Post of Director-General

A75/9
Sustainable financing: report of the Working Group

A75/10 Rev.1
Consolidated report by the Director-General

A75/16
Public health emergencies: preparedness and response
The Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme

A75/18
Strengthening WHO preparedness for and response to health emergencies
Proposal for amendments to the International Health Regulations (2005)

A75/19
Strengthening WHO preparedness for and response to health emergencies
Strengthening collaboration on One Health

A75/21
Strengthening WHO preparedness for and response to health emergencies
Universal Health and Preparedness Review: concept note

A75/22
Implementation of the International Health Regulations (2005)

A75/23
Poliomyelitis
Poliomyelitis eradication

A75/24
Poliomyelitis
Polio transition planning and polio post-certification

...
WHO Investment Case

A Healthy Return - Investment case for a sustainably financed WHO
17 May 2022 | Publication :: 44 pages
ISBN 978-92-4-005000-6 (electronic version)
ISBN 978-92-4-005001-3 (print version)
PDF: https://apps.who.int/iris/rest/bitstreams/1424321/retrieve

Executive summary
For more than 70 years, WHO has been the cornerstone of the global health architecture and has played the leading role in improving global health during a period of unprecedented improvement in human well-being and longevity. Today, the importance of improved health outcomes is increasingly recognized from an economic perspective, and the value of health capital as a whole may be at least as large as the value of all other forms of capital combined. Spending on health is an investment which underpins the quality of life, happiness and prosperity.

WHO's Thirteenth General Programme of Work, 2019–2023 focuses on making a measurable impact on people’s health in all countries. Its Triple Billion targets set the course for WHO to support the world to ensure that one billion more people benefit from universal health coverage, one billion more people are better protected from health emergencies, and one billion more people enjoy better health and well-being by 2023.

However, with disruptions caused by COVID-19 exacerbating slow progress toward the Triple Billion targets, the world is far off track to achieve these global goals. Extending the timeline of the Thirteenth General Programme of Work from 2023 to 2025 to achieve these targets is a necessary step.

Investment in WHO is catalytic by nature, meaning that funds invested in WHO are used to support Member States in taking action on health issues. This is done through the three key functions of WHO – leadership, development of technical products and country support. An example of catalytic action is development of technical products such as guidelines and the prequalification of medicines, vaccines and medical devices which through one process can achieve benefits in all 194 Member States.

According to a new analysis contained here, the quantifiable return on investment in WHO is very substantial. The cost of WHO in net present value terms over the coming 10-year period, 2022–2031, is US$ 33 billion and the public value created as a result of this investment, in the most conservative estimation possible, is likely to be between US$ 1.155 trillion and US$ 1.46 trillion. The resulting return on investment is US$ 35 for every US$ 1 invested in WHO.

The disruptive shock of the COVID-19 pandemic has sharpened global awareness of the value of health and the need for investment in it. Yet despite this, in the 2020–2021 biennium, only 16% of WHO’s budget was accounted for by assessed contributions, which are provided by all Member States.
Increasing the proportion of assessed contributions to cover a greater part of the base budget of WHO's programme budget would create a secure, sustainable financing stream, enabling a greater focus on fulfilling the core aims of the Organization.

There has never been a more critical moment to invest in WHO, and strengthen the unique role it plays in global health. Now is the time to sustainably finance WHO and invest in a healthy return for all.


3 In resolution EB150.R4, WHO's Executive Board recommended that the Seventy-fifth World Health Assembly in May 2022 extend the endpoint of the Thirteenth General Programme of Work by two years from 2023 to 2025.

COVID Perspectives

Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised 17 May 2022)

Joint Statement from the International Coalition of Medicines Regulatory Authorities and World Health Organization

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients. Vaccines play a critical role in preventing deaths, and hospitalisation caused by infectious diseases, and are contributing to controlling the spread of the disease, thus their impact on infection and serious illness is significant. Both vaccinated and unvaccinated people also need to be aware of the additional protective behaviours required to control the pandemic locally.

The global impact of the COVID-19 pandemic has resulted in an unprecedented level of public interest in vaccines. This includes a focus on the development of vaccines and their regulatory review and safety monitoring. Much of this coverage has taken place through mass and social media. Reports of adverse events (side effects) have led some people to express concerns about getting vaccinated, delay getting vaccinated or be strongly opposed to vaccination. There are also differences in individual confidence in national safety monitoring systems. Another challenge in communicating the importance of COVID-19 vaccination is that in many, but not all, children and young adults are less clinically affected by COVID-19 infection and therefore some may see limited value in vaccinating this population. Clear and consistent communication of evidence and uncertainties is therefore essential to support people in making the critical choice to be vaccinated.

We appreciate that you, your colleagues and your patients may have a number of questions around the development, regulatory review and ongoing safety monitoring of COVID-19 vaccines.

Purpose

This joint International Coalition of Medicines Regulatory Authorities (ICMRA)* and World Health Organization (WHO) statement aims to help healthcare professionals answer
questions about the role of regulators in the oversight of COVID-19 vaccines. It explains how vaccines undergo robust scientific evaluation to determine their safety, efficacy and quality and how safety is closely and continually monitored after approval.

Vaccination has been shown to contribute to reducing deaths and severe illness from COVID-19, and to reduce the transmission of COVID-19. Vaccinating as many people as possible and reducing the spread of disease is important. Vaccination of a significant proportion of the population also protects vulnerable people, including those who cannot receive vaccines, or the small proportion of people who might remain at risk of infection after vaccination. Failure to vaccinate widely also enables continued circulation of the virus and the generation of variants, including some that may pose a greater risk. Widespread vaccination has contributed to fewer people getting sick and being hospitalised, ultimately alleviating the burden of COVID-19 on healthcare systems. It has also helped allow the move back to normal societal functioning and the re-opening of economies...

Full text of statement available here

:::COVID Perspectives:::

COVAX calls for urgent action to close vaccine equity gap

This is a joint statement from the COVAX co-leads CEPI, Gavi, WHO, and UNICEF.

- COVAX has access to enough COVID-19 vaccines to help protect 70% of the population in 91 lower income countries
- Demand and uptake are low, with low-income countries remaining furthest behind
- To close the global vaccine equity gap, COVAX calls on countries to set ambitious targets for implementation and on all partners to ensure countries have the resources needed to accelerate and expand national strategies

Geneva/New York/Oslo, 20 May 2022 – Nearly 18 months after the first administration of a COVID-19 vaccine, incredible progress has been made – with lower-income countries administering billions of COVID-19 vaccines in a historic global rollout that is unprecedented in terms of speed, scale and demographics reached. Yet despite this progress, and the easing of global supply constraints, inequities between lower and higher income countries are continuing to cost lives and are prolonging the pandemic by increasing the threat posed by the emergence of new, potentially more dangerous variants of the virus.

Only 16% of people in low-income countries have received a single vaccine dose – compared to 80% in high-income countries. In certain lower-income countries, many of the most at-risk people in society – healthcare workers, the elderly and those with underlying health conditions – are going unprotected while young, healthy adults receive booster doses in wealthier countries.

The world must act urgently to close this equity gap.

After a year of severe constraints, we are now in a situation that two years ago would have seemed impossible: namely global supply is now high enough to underpin the overarching objective of supporting equitable, full vaccination of all adult and adolescent populations globally.
COVAX has access to more than enough doses needed to enable 91 lower-income countries that are supported by the COVAX Advance Market Commitment (AMC) – which provides donor-funded doses of a wide variety of COVID-19 vaccines – to meet their targets in light of the WHO global target of protecting 70% of the population in each country. **We can support these countries to meet individual targets and prioritize full coverage of high-risk groups.** In accordance with the updated SAGE roadmap of January 2022 – which recommends boosters for priority groups – COVAX is now open to and encouraging requests for doses for booster campaigns from countries.

COVAX is also well-placed to deliver these doses so they reach those in need. In just 15 months, COVAX – as the Vaccines Pillar of the ACT-Accelerator partnership for equitable access to COVID-19 tools – has shipped over 1.3 billion vaccines to 87 low and lower-middle income countries around the world.

**COVAX shipments account for 82% of vaccines delivered to low-income countries and the majority of COVID-19 vaccines administered in humanitarian settings.** Through driving the fastest, largest and most complex global vaccination effort in history, COVAX’s work has helped raise the average proportion of people protected by a full course of vaccines in these low- and lower-middle income countries to 46%.

The onus now is on building on this foundation to help countries to fully protect high risk groups, meet national vaccination targets, and close the global COVID-19 vaccine equity gap for good. **However, hurdles now remain: demand and uptake are low, with low-income countries remaining the furthest behind.**

**Demand and delivery**

With more than 3.8 billion COVID-19 doses administered to-date, national governments in lower-income countries have led the way. The number of countries with coverage under 10% of the population has decreased from 34 in January to 18 today. Some AMC-supported countries – for example, Bhutan, Cambodia, Viet Nam, Maldives, Fiji and Bangladesh – have coverage above 70%.

Building on country readiness efforts undertaken so far, the countries furthest behind are receiving tailored support. In January 2022, WHO, UNICEF and Gavi established the COVID-19 Vaccine Delivery Partnership (CoVDP), an inter-agency initiative building on existing resources globally, regionally and in-country to support COVID-19 vaccine delivery in lower-income countries. **CoVDP specifically provides urgent operational support to the 34 countries that were at or below 10% full vaccination coverage in January 2022, many of which are in Africa.** By mid-April 2022, a total of $29 million of urgent funding was coordinated and disbursed – within 15 working days or less – to ten countries across the three agencies. The CoVDP has driven political engagement with several countries with low vaccination rates to keep vaccine delivery on top of the political agenda and identify opportunities for bundling COVID-19 vaccinations with other health interventions.

While CoVDP and other efforts are helping lower-income countries make progress, challenges still need to be addressed. **In many countries Omicron has reduced the perceived risk of the virus and there are other health priorities that people and governments are focused on.** The option of integrating COVID-19 vaccination with other health systems activities – for example, measles and polio campaigns, or the distribution of malaria bed nets, – therefore becomes more important. COVID-19 vaccination is also an opportunity to strengthen health systems including training health workers,
enhancing health management information systems, further improving the cold chain, and forging new ways of working in fragile and conflict settings.

Through our continuous dialogue with AMC-supported countries, we know that demand is highly dynamic and difficult to predict, even for countries themselves. Thanks to input from national governments, COVAX is able to make some initial estimates of overall demand from AMC-supported countries. From our analysis of the latest demand planning forecasts provided to us by these countries, estimated country demand from now through early 2023 currently stands at approximately 330 million doses from COVAX, in addition to what has already been delivered or accepted by countries. However, these continue to be dynamic figures, and will evolve with situations on the ground as well as the occurrence of new variants. As such, COVAX will be working with national governments to continuously update these estimates.

In order for the world to continue to make meaningful progress on closing the global vaccine equity gap, we urgently call on countries to set ambitious targets backed by concrete plans for implementation – prioritising full coverage of high risk groups – and on all partners to coordinate on providing countries with the resources needed to accelerate and expand national strategies, stimulate demand and overcome operational bottlenecks. The next 3-4 months are crucial for accelerating COVID-19 vaccination campaigns, alongside moving to integrate COVID-19 vaccination efforts into routine primary health systems.

Supply

It is testament to the ground-breaking work of the scientific and manufacturing communities that there is now enough global supply to meet needs, as is the fact that it took only 327 days to go from the SARS-CoV-2 virus being sequenced and published to bringing a COVID-19 vaccine into emergency use.

As we strive to help countries deploy more doses, we must also work ensure supply remains available, at the right times. COVAX experienced delays securing doses in 2021. With many doses from advance purchase agreements now becoming available alongside donated doses, and the dynamic nature of country demand coupled with global oversupply, it is highly likely that overall supply will exceed demand. However, COVAX is working with manufacturers to help make supply more responsive to the changing demand environment.

That both global and COVAX supply now exceed demand is an advantageous situation in a pandemic, as it guarantees all countries long term availability of supply and choice of product. Protecting populations rapidly must now take priority. This is fundamental, given that 2021 clearly demonstrated the impact ad hoc, unpredictable supply had on the ability for countries with more limited health systems resources to plan and roll-out vaccination campaigns. Certainty of supply enables countries to plan national vaccination campaigns with more confidence, ensures a rolling buffer of stock can be available in-country and aids smooth and efficient roll outs.

While every effort should be taken to minimize wastage and expiry, lower income countries should also be able to accept doses, and to aim high, without being stigmatized when there is wastage, which is an inevitable part of immunization efforts against any disease, in any country.

COVAX is committed to providing countries with long-term, predictable supply, catering to all contexts and maintaining reserves to ensure supply can keep up with shifts in demand. This includes working
with manufacturers and donors to ensure any new, variant-adapted vaccines reach COVAX at the same time as higher income countries.

**We call on donor countries and manufacturers to support COVAX by ensuring the volume and timing of deliveries match as closely as possible the needs of lower-income countries. Donors should support COVAX in maintaining a diverse portfolio, including variant-adapted vaccines if necessary. Manufacturers should work with COVAX to re-phase or re-size supply from existing advance purchase agreements.**

A world beset by numerous challenges and crises does not change the fact that the pandemic – our collective crisis – is far from over. **Closing the vaccine equity gap must continue to be an urgent priority for the international community.**

---

**Unprecedented & Unfinished: COVID-19 and Implications for National and Global Policy**

International Science Council, May 2022 :: 110 pages

This new report from the ISC outlines plausible scenarios for the COVID-19 pandemic to consider the options for achieving the most desirable end to the crisis, highlighting that decisions made over the coming months and years need to be informed not only by short-term priorities but also by long-term challenges, and will serve as an analytical tool for policy-makers to lead to a more optimistic outcome to the pandemic.

**Executive Summary [Excerpt]**

**What are the key recommendations for how the global community prepares?**

Mapping the clocks, the vectors of uncertainty and the resulting outcomes provides an overview of the complexity of the pandemic’s impact and the multiple chain reactions that it has unleashed. Decisions and actions must be scrutinized in the context of cascading risks, complex feedback loops and multiple trade-offs.

Considering the multidimensional nature of the COVID-19 pandemic, Part 2 of the report outlines the most important lessons and policy implications that are widely applicable for either national or multilateral action. The aim is to suggest ways to shift the current trajectory towards a more optimistic outcome that is closer to the Collaboration Plus scenario.

Some of the **key recommendations** are shown in Table 1. These include the following:

1. Global and regional cooperation are essential as a core component of seeking remedies and ongoing protection. Current shortcomings in the multilateral system highlighted by the handling of the pandemic (and indeed of the Ukraine crisis) call for reform in the way this operates to handle major crises. This is especially the case given the need to navigate through COVID-19 while facing multiple risks related to climate change, geopolitical tensions, food security and other areas.

2. In order to address the widening inequalities that have resulted from the pandemic, governments need to focus on ensuring that the benefits of any future economic recovery are widely shared. This means investing in several areas of overlapping impacts, including: inclusive governance; the
acceleration of international mechanisms to ensure high-quality therapeutics for low-income countries; elimination of the digital divide in education; and mitigation of social isolation arising from the pandemic through mechanisms for engagement across society.

3. Governments must review and reframe the way they assess risk, integrating it more formally into policy development. Transdisciplinary thinking and a focus on resilience are required both before and during a crisis to increase preparedness for and resilience to a wide range of disasters, considering interconnected risks and consequences.

4. Governments must prioritize building and maintaining trust, help strengthen societal cohesion, and foster cooperation and resilience. Community engagement should be a central activity in preparedness plans for pandemics and other crises, with a diversity of views heard.

5. There is a need to address the challenges of disinformation, and to strengthen pluralistic science advice systems to increase trust in science, thereby protecting societies from risks.

6. Equally, there is a need invest in R&D for the public good. As part of this, the UN should develop a more integrated approach to science so that challenges can be overcome by working towards common goals.

7. Policy learning at the local, regional, national, and international level must be increased. This includes sourcing multiple kinds of data and knowledge to learn what precipitated events and what went wrong, in order to develop better mechanisms to address future risks.

**Key messages**
The pandemic has affected every society and is truly a global crisis. Policymakers have focused predominantly on national solutions. However, a global crisis requires global and regional cooperation and solutions, in addition to well thought-through national and local responses.

Although the pandemic will continue to affect every aspect of social, political, economic, and diplomatic life, many decision-makers continue to take a short-term perspective, neglecting the potential impact of their decisions on non-health-related policy domains far into the future.

This project provides a template for policy-makers and experts to consider local decisions in a wider context. It highlights the types of decisions that might lead to better and more equitable outcomes, and illustrates the complex interactions between these decisions.

The future course of the pandemic, and its consequences that extend well beyond the health regime, will depend on policy decisions taken today. Such decisions will shorten or prolong the course of the pandemic and mitigate or aggravate its impacts.

‘Clocks’
Clocks describe a policy dimension and the timeframe at which the outcomes of interest manifest. This conveys the realization that different parts of the global system change and evolve at different speeds and across different timeframes, all while interacting with each other. This report examines seven clocks (health, social, national governance, economics, global governance, environment, and science and technology).
## I. Vectors of uncertainty

<table>
<thead>
<tr>
<th>CLOCK</th>
<th>VECTORS OF UNCERTAINTY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Health</strong></td>
<td>Emerging viral variants of concern and surveillance systems</td>
</tr>
<tr>
<td></td>
<td>Global access to antivirals</td>
</tr>
<tr>
<td></td>
<td>Global access to effective vaccines</td>
</tr>
<tr>
<td></td>
<td>Global access to other essential health goods</td>
</tr>
<tr>
<td></td>
<td>Health system capacity/resilience</td>
</tr>
<tr>
<td></td>
<td>Public health and social measures</td>
</tr>
<tr>
<td></td>
<td>State of mental health</td>
</tr>
<tr>
<td><strong>Social</strong></td>
<td>Educational attainment</td>
</tr>
<tr>
<td></td>
<td>Employment structure</td>
</tr>
<tr>
<td></td>
<td>Participation in social networks and community organizations</td>
</tr>
<tr>
<td></td>
<td>Policies targeting inequalities</td>
</tr>
<tr>
<td></td>
<td>Provision of care services</td>
</tr>
<tr>
<td></td>
<td>Social protection measures</td>
</tr>
<tr>
<td></td>
<td>Violence or discrimination</td>
</tr>
<tr>
<td><strong>Economics</strong></td>
<td>Commodity price changes</td>
</tr>
<tr>
<td></td>
<td>Employment demanding growth</td>
</tr>
<tr>
<td></td>
<td>Extent of global trade disruption</td>
</tr>
<tr>
<td></td>
<td>Global tax system changes</td>
</tr>
<tr>
<td></td>
<td>Level of inflation</td>
</tr>
<tr>
<td></td>
<td>LMIC access to global capital markets</td>
</tr>
<tr>
<td></td>
<td>Private investment (including green investment)</td>
</tr>
<tr>
<td></td>
<td>Rising interest rates</td>
</tr>
<tr>
<td></td>
<td>Size of stimulus packages</td>
</tr>
</tbody>
</table>
| Environmental | Cascading risks of other disasters  
|               | Environmental degradation  
|               | Food, water and sanitation  
|               | Prioritization of One Health Initiative  
|               | Prioritization of SDGs and climate emergency  
| Science and technology | Crisis and disaster science  
|                    | Data management  
|                    | Open science policies  
|                    | R&D approach to managing epidemics  
|                    | Science education  
|                    | Spread of misinformation and disinformation  
| National governance | Engagement of the private sector  
|                    | Government capacity and resources (including subnational)  
|                    | Level of social unrest  
|                    | Level of State involvement in response to pandemic  
|                    | Multisectoral coordination  
|                    | National biosecurity and disaster preparedness  
|                    | Politicization of COVID response  
|                    | Science-informed policy and communication  
|                    | Social capital/trust in government  
|                    | Type of government in power (ideology)  
| Global governance | Effective regional mechanisms  
|                   | Engagement of the private sector  
|                   | Financing mechanisms for essential goods  
|                   | Geopolitical opportunism  
|                   | Global biosecurity/disaster preparedness  
|                   | Migration and freedom of movement  
|                   | Multi-/bilateral cooperation  
|                   | Multisectoral coordination  
|                   | State of multilateral institutions (authority)  |
Pandemic - Asylum Policy

UN High Commissioner for Refugees calls on states to lift remaining pandemic-related asylum restrictions

20 May 2022

More than two years on from the outbreak of the COVID-19 pandemic, at least 20 countries across the world today still deny access to asylum for people fleeing conflict, violence, and persecution based on public health measures. Some of these countries apply exceptions for the entry of asylum seekers in an inconsistent or arbitrary manner.

The latest figure of denial of access to asylum represents an improvement in how states handle the admission of asylum seekers since the onset of the pandemic. At the height of the emergency, 100 countries initially restricted access to asylum seekers, placing people already at risk in even more danger.

While states have the sovereign right to regulate the entry of non-nationals, the right to seek asylum and the prohibition of returns to situations of danger are central tenets of international law. This also prohibits countries from rejecting asylum seekers at borders.

“I appeal to the states that continue to maintain these restrictions to lift them urgently, in order to enable people to seek safety and protection,” said UN High Commissioner for Refugees, Filippo Grandi.

“With wars and violence raging across the world, and people fleeing from persecution, these measures deny the fundamental human right of people to seek asylum. Women, men and children continue to be turned away at land borders and sea; or are returned or transferred to countries where they may face threats to their life or freedom.”

UNHCR has repeatedly warned that measures that deny asylum seekers entry at borders are not only contrary to international law but are also not necessary to address public health risks.

Throughout the pandemic, UNHCR worked with and urged states to uphold their international legal obligations to asylum seekers and provided guidance and technical advice on how to safeguard the rights of refugees while also protecting public health.

The practice of most states, which admitted asylum seekers during the pandemic, shows that it is possible to manage public health risks, through, for example, testing and quarantine, and other reasonable and proportionate measures.

A recent evaluation on the protection of refugee rights during the pandemic found that some restrictive public health practices adopted at the height of the pandemic have been retained as security measures.
“I am worried that measures enacted on the pretext of responding to COVID-19 are being used as cover to exclude and deny asylum to people fleeing violence and persecution,” said Grandi. “COVID-19 cannot be an excuse to ignore the law and refugee rights.”

The UNHCR mapping of COVID-19 related border restrictions for asylum seekers is available here: https://data2.unhcr.org/en/dataviz/127

Vaccination in Conflicts Zones

**COVID-19: People living in conflict zones cannot be forgotten in global vaccination effort**

People living in warzones are at risk of being the very last in the world to have access to COVID-19 vaccines. Of the 25 countries with the lowest vaccination rates in the world today, more than half of them are embroiled in armed conflict and violence.

News release 18 May 2022
Geneva (ICRC) – Ahead of the World Health Assembly, the ICRC is shining a light on the millions of people who continue to be at risk from COVID-19: those living through conflict and armed violence who are yet to receive a single dose of a vaccine.

"Two years on, our fatigue around the pandemic cannot cloud the fact that it is not over and that new and potentially deadly virus variants remain a real threat to our return to normalcy and most importantly, human lives," Sophie Sutrich, head of ICRC's COVID-19 management team. "The Omicron variant shows what can happen when large pockets of people are unvaccinated, leading to viral replication and the possible emergence of variants that vaccines don't cover. Controlling this virus—and future viruses—will only be possible if we invest in health care systems and make sure that everyone is included in vaccination efforts, including those in hard-to-reach conflict zones."

The WHO estimates that the COVID-19 pandemic caused the deaths of nearly 15 million people globally, a devastating statistic that underscores both the urgency to make vaccines available to everyone and to invest in health care systems. Armed conflict takes a heavy toll on health care systems, leaving infrastructure damaged or neglected and complicating supply chains.

The ICRC, therefore, facilitates vaccinations in last-mile areas by helping gain access across frontlines through its neutral humanitarian work, and by helping with the logistics of transport and cold chains. Countries in conflict often have inherent challenges for carrying out vaccinations such as a lack of cold chain and storage capacities, a lack of electricity, poor health capacities due to a breakdown of health services, a lack of health personnel, and precarious infrastructure including difficult and underdeveloped road networks.
All too often in conflict zones, health care workers come under fire or are forced to flee. When doctors and nurses and the clinics and hospitals where they work aren't protected by parties to a conflict, their entire communities suffer. It often means people are left with nowhere to go to seek care, let alone COVID-19 vaccines.

The ICRC is working urgently to get vaccines in the arms of some of the most vulnerable populations, working with International Red Cross and Red Crescent Movement partners around the world to support COVID-19 vaccination in armed conflicts.

---

**Operational examples:**

**Colombia:**
The ICRC has negotiated in various occasions that the vaccination teams could access communities under influence of non-state armed groups for COVID-19 vaccinations.

**Myanmar:**
The ICRC in Myanmar has supported COVID-19 vaccination campaigns in health facilities near borders areas.

**Mozambique:**
The ICRC facilitates the transport of vaccines and Ministry of Health vaccination teams in conflict-affected districts in the central region and in the northern province of Cabo Delgado.

---

**Shots in arms**
The ICRC firmly believes that access to COVID-19 vaccines should be unconditional — no political, financial, legal or logistical aspect should curb the efforts to reach the people in conflict and the most fragile settings.

Having vaccine doses available is only part of the solution to this crisis. We must ensure that the vaccine makes it from the airport tarmac into the arms of the most vulnerable.

**Specifically, the ICRC calls on governments, non-state armed groups, vaccine manufacturers and donors to:**

1. Help produce and deliver more vaccines for countries suffering from conflict;
2. Provide greater investment in local delivery mechanisms and capacity to ensure vaccines leave the tarmacs of capital airports and reach people living across frontlines and remote areas;
3. Integrate COVID-19 vaccinations into a broader health strategy which strengthens and supports health care systems weakened by conflict and underinvestment; and
4. **Recognize the fundamental principle under International Humanitarian Law of 'prevention of disease' as a medical purpose, including the administration of vaccines, to ensure access to all those living in conflict areas.**

COVID-19 Vaccination: Support to people affected by armed conflict and violence and those living in hard-to-reach areas

17-05-2022 |
The ICRC is working with Red Cross and Red Crescent partners around the world to support COVID-19 vaccination in armed conflicts as well as hard-to-reach and volatile areas.

OPERATIONAL SUPPORT FOR COVID-19 VACCINATION PLANS
INTERNATIONAL COMMITTEE OF THE RED CROSS (ICRC)

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 20 May 2022
Confirmed cases :: 521 920 560
Confirmed deaths :: 6 274 323
Vaccine doses administered: 6 274 323

Weekly epidemiological update on COVID-19 - 18 May 2022
Overview
Globally, after the continued decline observed since the end of March 2022, new weekly COVID-19 cases have stabilized during the reporting period (9 May to 15 May 2022), with over 3.6 million cases reported, a 1% increase as compared to the previous week. The number of new weekly deaths
continues to decline, with over 9000 new deaths reported during the same period, representing a 21% decrease as compared to the previous week.

As of 15 May 2022, over 518 million confirmed cases and over six million deaths have been reported globally.

In this edition, we provide an update on:
- the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the prevalence.
- a special focus on environmental surveillance for SARS-CoV-2 to complement public health surveillance

![COVID-19 cases reported weekly by WHO Region, and global deaths, as of 15 May 2022**](image)

**Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 02 April 2022**

[New additions; Full scale view available at title link above]
[Updated on 02 Apr 2022]

**COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements**

[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

**AstraZeneca**

*Press Releases*

AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19
17 May 2022

**Bharat Biotech**

*Press Releases* - No new digest announcements identified
Biological E

News

**Biological E. Limited Reduces CORBEVAX Price to Rs.250 a Dose**

Hyderabad, May 16, 2022:

The reduced price aims at protecting the maximum number of children against the virus.

The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12.

Biontech

Press Releases

**Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age**

16 May 2022

- EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine at a time when Omicron was the prevalent variant.
- Children 5 through 11 years of age now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series.
- To date, 4,500 children 5 through 11 years of age have participated in the companies’ COVID-19 vaccine clinical trial.

**Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission**

16 May 2022

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified

Cinagen

Recent News

**Reports of unauthorized export and availability of counterfeit products of CinnaGen**

15 May 2022  [Specific products not identified]

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - See Russia below.

IMBCAMS, China
Janssen/JNJ
Press Releases - No new digest announcements identified

Medicago
Media - No new digest announcements identified

Moderna
Press Releases
18 May, 2022
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity

Nanogen
News - No new digest announcements identified

Novavax
Press Releases
May 20, 2022
Statement
Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over

Pfizer
Recent Press Releases
05.17.2022
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
- EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine at a time when Omicron was the prevalent variant
- Children 5 through 11 years of age now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
- To date, 4,500 children 5 through 11 years of age have participated in the companies’ COVID-19 vaccine clinical trial

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified
Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBBP
News - No new digest announcements identified

Sinovac
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - No new digest announcements identified [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

GSK
Press releases for media - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Novartis
News - No new digest announcements identified

SK Biosciences
Press Releases
SK bioscience and the Bill & Melinda Gates Foundation Agreed to Strengthen Partnership
2022.05.17

Valneva
Press Releases
May 19, 2022
EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 Vaccine Candidate

May 16, 2022
Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement – Webcast Link

May 16, 2022
Valneva Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 21 May 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

COVID-19 Global Targets and Progress Tracker - IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)
The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 21 May 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/
Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID Vaccines – OCHA:: HDX

**COVID-19 Data Explorer: Global Humanitarian Operations**

**COVID-19 Vaccine Roll-out**

21 May 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 517M total confirmed cases; 6.3M total confirmed deaths

Global vaccines administered: 11.8B

Number of Countries: 28

COVAX Allocations Round 4-9 (Number of Doses): 170M

COVAX Delivered (Number of Doses): 300M

Other Delivered (Number of Doses): 330M

Total Delivered (Number of Doses): 620M

Total Administered (Number of Doses): 410M

**Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 21 May 2022: https://data.covid19taskforce.com/data. The global view below is complemented by country-specific dashboards here.

---

**Our World in Data**

:: 65.7% of the world population has received at least one dose of a COVID-19 vaccine.
:: 11.76 billion doses have been administered globally, and 7.13 million are now administered each day.
:: Only 15.9% of people in low-income countries have received at least one dose.
HHS

Statement from HHS Secretary Xavier Becerra on FDA and CDC Expanding Eligibility for Pfizer-BioNTech COVID-19 Vaccine Boosters for 5-11 Year Olds
May 19, 2022 | News Release

BARDA-ASPR – U.S. Department of HHS  [to 21 May 2022]
https://aspr.hhs.gov/newsroom/Pages/NewsRoomHome.aspx

HHS commits up to $300 million over 10 years to combat antibiotic-resistant bacteria
May 19, 2022

The U.S. Department of Health and Human Services (HHS) will commit $20 million this year and has options to provide up to $300 million over the next 10 years to combat antimicrobial resistant (AMR) infections through the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This public-private partnership is dedicated to accelerating the early development of therapeutics, preventatives and diagnostics for AMR infections...
FDA
Press Announcements
May 17, 2022 - Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years

Regulatory Actions
Vaccines and Related Biological Products Advisory Committee- FDA

Calendar
:: On June 7, FDA intends to convene VRBPAC to discuss an EUA request for a COVID-19 vaccine manufactured by Novavax to prevent COVID-19 in individuals 18 years of age and older.
:: On June 8, 21 and 22, the FDA has held dates for the VRBPAC to meet to discuss updates to the Moderna and Pfizer-BioNTech EUAs for their COVID-19 vaccines to include younger populations. As the sponsors complete their submissions and the FDA reviews that data and information, it will provide additional details on scheduling of the VRBPAC meetings to discuss each EUA request.
:: On June 28, the FDA plans to convene the VRBPAC to discuss whether the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified, and if so, which strain(s) should be selected for Fall 2022. This meeting is a follow-up to the April 6 VRBPAC meeting that discussed general considerations for future COVID-19 vaccine booster doses and the strain composition of COVID-19 vaccines to further meet public health needs.

...Once the meeting dates are finalized, the FDA intends to make background materials available to the public, including the meeting agenda and committee roster, no later than two business days before each meeting...

:::::

White House [U.S.]  [to 21 May 2022]
Briefing Room – Selected Major COVID Announcements
[See announcements associated with the 2nd Global COVID-19 Summit above]
Press Briefing by White House COVID-19 Response Team and Public Health Officials | May 18, 2022
May 18, 2022 • Press Briefings

Fact Sheet: The Biden Administration Announces Americans Can Order Additional Free At-Home, Rapid COVID-19 Tests at COVIDTests.gov
May 17, 2022 • Statements and Releases

USAID [to 21 May 2022]
Selected Press Releases, Statements, Announcements
USAID Announces $8 Million in Additional Humanitarian Assistance for People Affected by Super Typhoon Rai and Tropical Storm Megi in the Philippines
May 21, 2022

The United States, through the U.S. Agency for International Development (USAID), is providing an additional $8 million in humanitarian assistance for people experiencing continuing humanitarian needs associated with Super Typhoon Rai and subsequent Tropical Storm Megi in the Philippines. Building on support provided for the initial disaster response, this new funding brings total USAID assistance for typhoon-affected people in the Philippines to more than $29 million since December 2021.

The United States Announces Additional Funding to Respond to Global Food Insecurity
May 18, 2022

At the Global Food Security Call to Action Ministerial Meeting convened by the United States today in New York, Secretary of State Antony Blinken announced nearly $215 million in additional humanitarian assistance to address the global food security crisis, which has been exacerbated by Russia’s war on Ukraine and its corresponding impact on global markets. Even before the war began, approximately 768 million people were chronically hungry. This new crisis has only made an already dire situation significantly worse, with as many as 40 million people projected to be pushed into poverty and food insecurity through the end of the year.

::::::

::::::

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022 (new)
CHMP, Last updated: 20/05/2022

News: International regulators and WHO: support healthcare professionals to enhance public confidence in COVID-19 vaccines (new)
Last updated: 17/05/2022

EMA has endorsed a statement for healthcare professionals jointly developed by the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO). The statement is aimed to help healthcare professionals answer questions about the role of regulators in the oversight of COVID-19 vaccines and to reassure medical staff about the safety of COVID-19 vaccines that undergo a robust scientific evaluation to determine their quality, safety and efficacy.

ICMRA and WHO also highlight the measures put in place nationally and globally to continuously monitor the safety of COVID-19 vaccines that are used in countries worldwide...
[See COVID Perspectives above for detail]

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates [Selected]
News
Epidemiological update: Monkeypox outbreak
Epidemiological update - 20 May 2022
As of 16 May 2022, there is a multi-country outbreak of monkeypox affecting the UK, EU/EEA states, and North America. As of 20 May 2022, there have been a total of 38 confirmed cases reported worldwide, 37 of which have no history of travel to endemic countries.

| Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-05-19 |
|-----------------------------------------------|----------------|----------------|
| At least one dose                             | Primary course | Booster/additional dose |
| 75.4%                                         | 72.7%          | 51.8%           |

European Commission
https://ec.europa.eu/commission/presscorner/home/en

Press release 20 May 2022
Humanitarian aid: EU releases additional €22 million in Bangladesh and Myanmar
The Commission is releasing an extra €22 million in humanitarian aid to ensure life-saving support for hundreds of thousands of Rohingya refugees and host communities in Bangladesh, as well as Rohingya and other conflict-affected people in Myanmar.

Press release 19 May 2022
Member States, workers and employers agree on the need to recognise COVID-19 as an occupational disease
Yesterday, Member States, workers and employers in the EU Advisory Committee on Safety and Health at Work (ACSH) reached an agreement on the need to recognise COVID-19 as an occupational disease.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/
Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Latest Updates [Selected]
[No new digest content identified; last announcement at 28.03.2022]

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
[Website not responding at inquiry...graphic below from last week]
Government of India – Press Information Bureau
Latest Press Releases
COVID-19 Vaccination Update - Day 491
:: India’s cumulative vaccination coverage crosses 192.26 Crore
:: More than 12lakh Vaccine doses administered today till 7 pm
Posted On: 21 MAY 2022 8:41PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[We did not identify official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations, leading us to include these reports/observations from the general media below. See China CDC below for additional announcements]

Shanghai makes way towards COVID lockdown exit, Beijing plays defence
Reuters, May 21, 2022 8:02 AM EDT Last Updated 9 hours ago
By Eduardo Baptista
- Shanghai cautiously works to restore transport services
- Shanghai reports mostly zero new community cases this week
- Beijing on edge as new infections keep appearing

Coronavirus: China travel made easier from more than 12 countries, including Britain, France and Japan
- Negative PCR result from a week ago and antibody test no longer required, multiple embassies say, days after similar notice for US flights
- Effective times vary from immediate to weeks later in June, but mandatory quarantine on arrival to stay
Phoebe Zhang
South China Morning Post, Published: 7:00pm, 20 May, 2022

Covid shows that in China, politics matters more than pragmatism
Why officials are so strangely slow to vaccinate the elderly
The Economist, 19 May 2022

The Collateral Damage in China’s COVID War
Are Beijing’s Harsh Measures Undermining Its Hold On Power?
By Yanzhong Huang
May 17, 2022
GPEI Polio

Polio this week as of 18 May 2022

Headlines
:: Ahead of the WHO World Health Assembly (WHA) taking place from 22-28 May 2022, the GPEI has prepared two reports which will inform Member State discussions, namely on polio eradication, and on polio transition planning and post-certification. The reports are available on this page.

Summary of new polioviruses this week:
– Chad: one cVDPV2 case
– Mozambique: one WPV1 case and three cVDPV2 cases
– Niger: one cVDPV2 case and two positive environmental samples
– Nigeria: three cVDPV2 cases and five positive environmental samples
– Togo: one cVDPV2 case

UN OCHA – Current Emergencies

Current Corporate Emergencies

Afghanistan
No new updates identified.

Northern Ethiopia
No new updates identified.

Ukraine

Ukraine: Situation Report - Last updated: 19 May 2022
- Eastern Ukraine remains the centre of hostilities, while airstrikes and missile attacks continue to be reported in multiple oblasts in Ukraine.
- Humanitarian conditions deteriorate while needs grow, primarily in southern and eastern Ukraine, with wide-scale disruptions to electricity, gas and water supplies.
- Municipal authorities and the World Health Organization warn of the potential outbreak of diseases, including cholera, in Mariupol due to unsanitary conditions.
- As of 12 May, the UN and humanitarian partners have reached over 6.4 million people in need across Ukraine.
- Over 5.7 million people received food assistance and 1.5 million health-related support from the UN and humanitarian partners since 24 February.

WHO & Regional Offices [to 21 May 2022]
https://www.who.int/news
13 May 2022
Departmental news
WHO launches new Mortality Database visualization portal

13 May 2022
Departmental news

TB laboratory manuals issued to support the implementation of WHO-recommended diagnostics

12 May 2022
News release

WHO and MPP announce agreement with NIH for COVID-19 health technologies

12 May 2022
Departmental news

New report shows progress and missed opportunities in the control of NCDs at the national level

10 May 2022
Statement

World leaders urged to make firm commitments at Second Global COVID-19 Summit by ACT-Accelerator agency leads

::::

WHO Director General Speeches [selected]
https://www.who.int/director-general/speeches

Selected
12 May 2022
Speech

WHO Deputy Director-General's speech – Partnering to build sustainable Health Eco-System in Africa, African-European Collaboration

12 May 2022
Speech

WHO Director-General’s live speech at 2nd Global COVID Summit – 12 May 2022

10 May 2022
Speech

WHO Director-General’s remarks at the Special Session of the WHO Regional Committee for Europe — 10 May 2022

10 May 2022
Speech

WHO Director-General’s opening remarks at the WHO press conference – 10 May 2022

::::::

WHO Regional Offices
Selected Press Releases, Announcements
**WHO African Region**

:: **Southern Africa faces uptick in COVID-19 cases**

12 May 2022  Brazzaville – Southern Africa is facing an upsurge in COVID-19 cases for the third consecutive week as the winter season in the region approaches. The uptick has broken a two-month-long decline in overall infections recorded across the continent.

The sub-region recorded 46,271 cases in the week ending on 8 May 2022, marking a 32% increase over the week before.

**WHO Region of the Americas** PAHO

:: 10 May 2022  **Technical Note: acute, severe hepatitis of unknown origin in children**

This technical note follows the previous reports regarding the event of acute, severe hepatitis of unknown origin in children disseminated by the Pan American Health Organization / World Health Organization (PAHO/WHO) on 23 April 2022 (two reports), 25 April 2022, and 29 April 2022. This event was first reported by the United Kingdom...

**WHO South-East Asia Region** SEARO

*No new digest content identified.*

**WHO European Region** EURO

:: **Two million confirmed deaths from COVID-19 in the European Region** 12-05-2022
:: **Setting up a behavioural insights unit - WHO launches a set of considerations to support countries** 12-05-2022
:: **“What stays with me is the feeling of helplessness” – on International Nurses Day, a young nurse recalls her time on a COVID-19 ward at the beginning of the pandemic** 12-05-2022

**WHO Eastern Mediterranean Region** EMRO

:: **Palestinian Ministry of Health launches polio vaccination campaign to boost immunity in Bethlehem and Jerusalem** 13 May 2022
:: **Somalia launches WHO emergency health response plan for drought** 11 May 2022
:: **Environmental surveillance for poliovirus introduced in Iraq** 10 May 2022

**WHO Western Pacific Region**

*No new digest content identified.*

::::::

**Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

13 May 2022  | **Lassa fever - Guinea**

12 May 2022  | **Middle East respiratory syndrome coronavirus (MERS-CoV) - Qatar**

9 May 2022  | **Avian Influenza A(H3N8) - China**

::::::
WHO Events
https://www.who.int/news-room/events/1
[Selected]

Seventy-fifth World Health Assembly WHA 75
22-28 May 2022
:: Provisional agenda A75/1 Rev.1
[See Milestones above]

::::

New WHO Publications
https://www.who.int/publications/i
Selected Titles
20 May 2022
Understanding the behavioural and social drivers of vaccine uptake WHO position paper – May 2022

19 May 2022
Emergency in Ukraine: external situation report #12, published 19 May 2022: reporting period: 12–18 May...

19 May 2022
Background document on the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19

19 May 2022
Annexes to the interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against...

19 May 2022
Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19

18 May 2022
WHO information note on ensuring continuity of essential tuberculosis services for people with or at...

18 May 2022
Report of the second meeting of the WHO Technical Advisory Group on Diabetes: virtual meeting, 16–17...

18 May 2022
WHO Strategic Priorities on Antimicrobial Resistance

18 May 2022
Report of the first meeting of the WHO global diabetes compact forum: virtual meeting, 10–11 November...
18 May 2022
Stronger collaboration for an equitable and resilient recovery towards the health-related Sustainable...

17 May 2022
National workforce capacity to implement the essential public health functions including a focus on emergency...

17 May 2022
A Healthy Return
[See Perspectives above for detail]

17 May 2022
Implementation of the Initiative for coordinated antidotes procurement in the South-East Asia Region...

16 May 2022
HIV self-testing at workplaces: approaches to implementation and sustainable financing

16 May 2022
WHO Procurement Report 2021

15 May 2022
Global Report on Assistive Technology
Overview
There is a large, unmet need for assistive technology worldwide. The Global Report on Assistive Technology was developed in response to the World Health Assembly resolution (WHA71.8) on improving access to assistive technology adopted in May 2018. The Global Report is expected to play an instrumental role in setting the global roadmap for improving access to assistive technology for everyone, everywhere.

The Global Report on Assistive Technology presents a comprehensive dataset and analysis of current assistive technology access, drawing the attention of governments and civil society to the need for, and benefit of, assistive technology, including its return on investment. The Global Report sets out ten recommendations for improving access to assistive technology, which in turn support the achievement of the Sustainable Development Goals, inclusive Universal Health Coverage, and alignment with the Convention on the Rights of Persons with Disabilities.

Guided by an Expert Advisory Group, the WHO and UNICEF have jointly developed this report in the context of an integrated approach, based on the best available scientific evidence and international experience, in collaboration with stakeholders from diverse settings, multiple countries, and all regions. It is primarily directed at policy-makers, providers of assistive technology, donors and funding agencies, and industry leaders. It is also aimed at broader stakeholders including users and potential users of assistive technology and their families or caregivers.

13 May 2022
Practical manual of processing stool samples for diagnosis of childhood TB
13 May 2022
Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for...

13 May 2022
Vaccines against influenza: WHO position paper – May 2022

13 May 2022
WHO advisory committee on variola virus research: report of the twenty-third meeting, virtual meeting,...

CDC/ACIP [U.S.] [to 21 May 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html

Latest News Releases

Update on Children with Acute Hepatitis of Unknown Cause
Wednesday, May 18, 2022

ACIP Meetings
Next ACIP Meeting
May 19, 2022. 11:00am – 4:00pm ET
Agenda – May 19, 2022
Presentations

MMWR Weekly: Current Volume (71) May 20, 2022 / No. 20
PDF of this issue

Factors Associated with Use of HIV Prevention and Health Care Among Transgender Women — Seven Urban Areas, 2019–2020
Rabies in a Dog Imported from Azerbaijan — Pennsylvania, 2021

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 15 announcements/reports/data summaries.
:: 5/21/22 Cases in the U.S.
:: 5/21/22 Overall US COVID-19 Vaccine Distribution and Administration Update as of Sat, 21 May 2022 06:00:00 EST
:: 5/20/22 COVID-19 Vaccine Recommendations for Children and Teens
What You Need to Know
CDC recommends everyone ages 5 years and older get vaccinated against COVID-19.
Everyone ages 12 years and older should also get a COVID-19 booster shot.

<table>
<thead>
<tr>
<th>Authorized for</th>
<th>Pfizer-BioNTech</th>
<th>Moderna</th>
<th>J&amp;J/Janssen</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 years and under</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5-11 years old</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>12-17 years old</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Currently, the Pfizer-BioNTech COVID-19 vaccine is the only vaccine authorized or approved for children ages 5 through 17 years. Children and teens need two doses of a Pfizer-BioNTech vaccine. Everyone ages 12 years and older should also get a booster shot...

Africa CDC  [to 21 May 2022]
http://www.africacdc.org/
News
Singapore and the African Union can digitally verify each other’s COVID-19 Vaccination Certificates from 23 May 2022

Communique
Communique: West African High Level Vaccines Manufacturers Meeting
17 May 2022
[Excerpts]
...We the stakeholders in Vaccines Manufacturing in the West Africa Region under the leadership of ECOWAS/WAHO and Africa CDC met in Accra, Ghana from May 10th to 11th, 2022 to discuss on how to collaborate to ensure the production and availability of quality, safe and efficacious vaccines in the region...

The main objective of the high-level meeting is to create a framework for collaboration, information exchange and develop a framework for vaccines producers in the West African region to discuss strategically how to support each other build the regional hub for vaccines production.

Specifically, the meeting aims to:
- Identify the bottlenecks in vaccines research and development and production.
- Identify and define the types of vaccines to be produced for the region by each manufacturer.
- Define short, medium, and long-term strategies to boost vaccines production in the region
- Engage more partners and biotechnology developers to liaise with manufacturers...
**Recommendations:**

[1] The meeting agreed on types of vaccines to be produced in the region into considering that diversification of vaccines products (combining child immunization programs and adult vaccination programs that will require demand generation) will also help support manufacturers.

This includes twenty-two (22) identified vaccines which were further divided into 3 based on current and planned vaccine manufacturer’s capacities and capabilities in terms of short-term, medium-term and long-term depending on the period of production.

**Short term:** Yellow Fever vaccines, Anti snake serum, Covid-19 vaccines, Pentavalent, Rabies, Measles, Ebola, Typhoid, Lassa, Rotavirus, Tetanus and Polio Vaccines (IPV)- 2022 to 2024

**Medium term:** Human papillomavirus (HPV), Pneumococcal (PCV3), Polio Vaccine bOPV-4 (oral), Malaria, Measles MMR, BCG, HepB-Pediatric, Meningitis A and 2025 -2027

**Long-term:** Anti-cancer, 2028 to 2030...

**REQUESTS:**
1. Heads of Governments, Health Ministers, Ministers of Industries and relevant Ministries to help facilitate adoption of the recommendations of this meeting by providing stronger political commitment.
2. ECOWAS/WAHO to engage stakeholders, technical and financial partners to fund the vaccines manufacturing in the region.
3. That national vaccines manufacturing plans are aligned with the regional and continental plans to prevent duplication of efforts.
4. ECOWAS/WAHO to follow up with stakeholders to ensure that the regional priorities are achieved.

:::::::

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People’s Republic of China** [to 21 May 2022]
http://en.nhc.gov.cn/

*News*

**May 21: Daily briefing on novel coronavirus cases in China**

On May 20, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 201 new cases of confirmed infections.

**National Medical Products Administration – PRC** [to 21 May 2022]
http://english.nmpa.gov.cn/
*News*

**Chinese mainland reports 176 new local confirmed COVID-19 cases**

2022-05-20

The Chinese mainland on Thursday reported 176 locally-transmitted confirmed COVID-19 cases, of which 88 were in Shanghai, according to the National Health Commission’s report Friday.

**CCDC** **Weekly Reports: Current Volume (4)**
Editor's Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity [to 21 May 2022]
https://www.airfinity.com/insights
INSIGHTS & COMPANY NEWS
No new digest content identified.

Paul G. Allen Frontiers Group [to 21 May 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation [to 21 May 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 21 May 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
After celebrating its five-year anniversary in 2021, CARB-X (part of Boston University) announces renewed support from the U.S. Department of Health and Human Services (HHS) and Wellcome Trust, a U.K.-based global charitable foundation. The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within HHS, will provide US$20 million initially and up to US$300 million over 10 years to support the existing portfolio and launch new funding rounds. Wellcome will provide up to US$70 million over three years as part of its continued commitment to address the escalating threat of drug-resistant infections. Initial funding of $355 million from both BARDA and Wellcome originally launched CARB-X in 2016, and the new funding announced today builds on the success of this international non-profit partnership.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation**

https://centerforvaccineethicsandpolicy.net/

:: Past weekly editions of **Vaccines and Global Health: The Week in Review** are available here.
:: **Informed Consent: A Monthly Review – May 2022** is now posted here.
:: **Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022** is now posted here.

**CEPI – Coalition for Epidemic Preparedness Innovations**

http://cepi.net/

*Latest News*

20 May 2022

**COVAX calls for urgent action to close vaccine equity gap**

Partners issue joint statement as supply constraints ease but inequity persists

[See COVID Perspectives above for detail]

18 May 2022

**Sabin Vaccine Institute receives up to $6.3 Million from CEPI for dose-optimising COVID-19 vaccine clinical trial**

The research will allow us to understand if smaller doses of COVID-19 vaccines generate similar immune responses to full doses.

18 May 2022

**CEPI and GHIT collaborate to advance the global fight against infectious diseases**

MoU will strengthen collaboration between the two organizations, supporting both agencies to deliver on their missions.

**DARPA – Defense Advanced Research Projects Agency [U.S.]**
Duke Global Health Innovation Center  [to 21 May 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP  [to 21 May 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center  [to 21 May 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
New Emory TB research center to help draw attention to an old but still deadly disease
April 28, 2022

European Vaccine Initiative  [to 21 May 2022]
http://www.euovaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid  [to 21 May 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
National approaches to the vaccination of recently arrived migrants in Europe Added May 18, 2022
Screening migrants for infectious diseases in Europe Added May 16, 2022

Fondation Merieux  [to 21 May 2022]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation co-organized event
**Pioneering Ebola Response**
May 24, 2022 - Milken Institute School of Public Health

Register
Context - Symposium honoring Jean-Jacques Muyembe Tamfum
   A model for local leadership to address emerging infectious disease Challenges and opportunities for future detection of pandemic threats
Tuesday, May 24, 2022 – 10:00 – 11:30 (EDT)

**Gavi** [to 21 May 2022]
https://www.gavi.org/
*News Releases*
19 May 2022
**COVAX calls for urgent action to close vaccine equity gap**
[See COVID Perspectives above for detail]

**GHIT Fund** [to 21 May 2022]
https://www.ghitfund.org/newsroom/press
*Press Releases*
May 18, 2022
**CEPI and GHIT collaborate to advance the global fight against infectious diseases**

**Global Fund** [to 21 May 2022]
*News & Stories*
20 May 2022
**Global Fund Signs Letter of Intent with Pfizer for Oral COVID-19 Treatment**
   The Global Fund has signed a letter of intent with Pfizer for the procurement of up to 6 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™, in 2022-2023.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 21 May 2022]
https://www.glopid-r.org/news/
*News*
*No new digest content identified*

**Hilleman Laboratories** [to 21 May 2022]
http://www.hilleman-labs.org/
*News & Insights*
*No new digest content identified*

**HHMI - Howard Hughes Medical Institute** [to 21 May 2022]
Spying on Thousands of Neurons in the Brain’s Vision Center Simultaneously

Neurons across eight areas of the brain team up to process visual information. Researchers have now documented these neurons’ activity at a breadth and resolution never before reported.

Human Vaccines Project  [to 21 May 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI  [to 21 May 2022]
https://www.iavi.org/
Latest News
FEATURES
May 18, 2022
IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine development program
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity

May 17, 2022
HVAD 2022: An HIV vaccine developed with the people it seeks to benefit most
On this HVAD, our colleagues share perspectives on how an HIV vaccine can be developed with the people it seeks to benefit most.

ICRC  [to 21 May 2022]
What’s New  [Selected]
African Union and ICRC Marks 30 years of Partnership on Humanitarian Issues
20-05-2022 | Statement

COVID-19: People living in conflict zones cannot be forgotten in global vaccination effort
People living in warzones are at risk of being the very last in the world to have access to COVID-19 vaccines.
18-05-2022 | News release
[See COVID Perspectives above for detail]

COVID-19 Vaccination: Support to people affected by armed conflict and violence and those living in hard-to-reach areas
The ICRC is working with Red Cross and Red Crescent partners around the world to support COVID-19 vaccination in armed conflicts as well as hard-to-reach and volatile areas.
17-05-2022 | Article
[See COVID Perspectives above for detail]
International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 21 May 2022]
Press Releases [Selected]
**IFRC report: Goals for poverty reduction, decent work and closing inequality gap, stalled by COVID-19 in Latin America and the Caribbean**
20/05/2022 | Press release

**IFRC president: Ethnicity and nationality should not be deciding factors in saving lives**
16/05/2022 | Press release

Institut Pasteur [to 21 May 2022]
Press Documents
Press release
18.05.2022
**Phage Therapy: A Model to Predict Its Efficacy against Pathogenic Bacteria**
Antibiotic resistance represents a major public health challenge, associated with a high mortality rate.

IOM / International Organization for Migration [to 21 May 2022]
*News - Selected*
20 May 2022
**First United Nations Forum on International Migration Concludes Today**

20 May 2022
**Over 700,000 Affected by Cyclone Gombe in Mozambique Still in Need of Humanitarian Assistance as IOM Scales up Response**

20 May 2022
**Common Ground needed on Clear, Equitable Pandemic Travel Measures**
...IOM Director General António Vitorino, MPI President Andrew Selee, and several participants voiced their support for the creation of a Member State-led Group of Friends to discuss cross-border mobility
and pandemic preparedness, to complement and support the ongoing review of the International Health Regulations, and Member State negotiations towards a new pandemic treaty.

“Without this common endeavour, there is an increasing risk that future migration will become even more fragmented, accentuating the already evident signs of a two-speed recovery from COVID-19 that leaves less developed countries behind,” said DG Vitorino.

“This, in turn, will stall future economic and social development that could otherwise be accelerated through well-managed migration.”...

19 May 2022
**Over 59 Million People Internally Displaced in 2021: IDMC Report**

18 May 2022
**IOM and UNICEF Sign New Strategic Collaboration Framework**

**ISC / International Science Council**  [to 21 May 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
Press releases
**COVID-19 likely to worsen inequalities for at least five years without renewed global cooperation, warns International Science Council**
16.05.2022
[See COVID Perspectives above for detail]

**International Organization for Standardization (ISO)**  [to 21 May 2022]
https://www.iso.org/news
**News**
**New guidelines for COVID testing**
11 May 2022
A new ISO technical specification will improve testing procedures and contribute to a safer world.
... Recently published, ISO/TS 5798 provides recommendations for the design, development, verification, validation and implementation of analytical tests for detecting the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) using nucleic acid amplification. It addresses pre-examination, examination and post-examination process steps for human specimens...

**International Union of Immunological Societies (IUIS)**
https://iuis.org/
**News/Events [Selected]**
No new digest content identified.

**IVAC**  [to 21 May 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
**Updates; Events**
Webinar: Official Launch of the VERSE Equity Toolkit for Multidimensional Equity Assessments
Register Here
When: May 25, 2022 9:00 AM – 10:30 AM EST
Description: To identify what issues impair vaccine coverage, researchers traditionally look for an association with just one variable — wealth, for example — instead of examining the host of factors in play. Typical equity metrics may not appropriately account for the compounding effect of geographic and sociodemographic factors on immunization outcomes, such as, in the case of pediatric immunization, where a household is located, the sex of a child being vaccinated, and maternal education level. The VERSE Equity Toolkit compares the level of vaccine coverage against the level of equity and quantifies the influence of key sociodemographic factors to inequity.

IVI [to 21 May 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 21 May 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

MSF/ Médecins Sans Frontières [to 21 May 2022]
http://www.msf.org/
Latest [Selected Announcements]
No new digest content identified.

National Academy of Medicine - USA [to 21 May 2022]
https://nam.edu/programs/
News [Selected]
NAM Provides Opportunity for Public to Inform National Plan for Health Workforce Well-Being
May 20, 2022
Given the current shortage and burnout crisis faced by the health workforce, the National Academy of Medicine (NAM) Action Collaborative on Clinician Well-Being and Resilience is working urgently to deliver a National Plan for health workforce well-being in June 2022, and today released a draft plan for public input. The National Plan intends to provide [...]
Lack of representation in research is compounding disparities in health outcomes with serious consequences for underrepresented groups and the nation as a whole. Urgent actions are needed by NIH FDA and others to boost representation of racial and ethnic minority groups and other underrepresented populations in clinical trials and research.

National Academies of Sciences, Engineering, and Medicine (2022; 440 pages)

National Vaccine Program Office - U.S. HHS [to 21 May 2022]
https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

NVAC 2022 Meetings - June 15-16, 2022

NIH [to 21 May 2022]
http://www.nih.gov/

News Releases

Cancer death rates among Black people declined over time, but remain higher than other racial and ethnic groups
May 19, 2022 — Scientists used death certificate data to analyze age-adjusted cancer death rates.

Depression, loneliness associated with increased hospitalization risk after COVID-19, NIH-funded study suggests
May 19, 2022 — Scientists analyzed survey data from more than 54,000 female nurses and their children.

NIH announces antiviral drug development awards
May 18, 2022 — Scientists will seek to develop potential antivirals for COVID-19 and viral families with high potential to cause future pandemics.

Scientists identify characteristics to better define long COVID
May 16, 2022 — Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the condition.

Researchers identify the high costs of living with sickle cell disease
May 16, 2022 — Potential curative therapies may help reduce the burden, but are also costly.

Nuffield Council on Bioethics
https://www.nuffieldbioethics.org/news

News
17 May 2022

Ethics tools for decision-makers: Responding to public health threats
Throughout the COVID-19 pandemic, the Nuffield Council on Bioethics has consistently raised the importance of transparency in decision-making, especially the values that inform decisions.

Our latest publication 'Ethics tools for decision-makers: Responding to public health threats' aims to help decision-makers with this. Drawing on our in-depth work on public health ethics, these tools explain what action decision-makers can take to develop a proportionate response to public health threats, guided by important public values such as reducing suffering, being fair and being respectful.
Summary
- The state has responsibilities to enable people to live healthy lives and reduce health inequalities.
- There are no easy answers, but responses to public health threats can be guided by the values of reducing suffering, treating people with respect, and fairness.
- Options for public health interventions range from doing nothing to removing choice altogether.
- Decision makers should aim for a proportionate response that takes into account the nature and degree of the harm posed, the certainty of the evidence, the intrusiveness of the intervention, and the views of those affected.
- The application of each intervention is likely to generate further ethical questions and decision makers need to be alert to the need for transparency and accountability in decision making processes.

The tools include a version of our widely used ladder for public health interventions, adapted with examples for responding to COVID-19. Katharine Wright, lead author and Assistant Director of the Nuffield Council on Bioethics, said: “Public health threats such as COVID-19 are ethically challenging because they cannot be managed effectively by individuals alone, and any action taken will have broad and relatively indiscriminate impact. We believe looking at the problem through an ethics lens can help us reach good decisions about how to respond.”

PDF: https://www.nuffieldbioethics.org/assets/pdfs/Ethics-tools-for-decision-makers-FINAL1.pdf
Sabin Vaccine Institute Receives up to $6.3 Million from CEPI for Dose-Optimizing COVID-19 Vaccine Clinical Trial

Tuesday, May 17, 2022

WASHINGTON, D.C. – The Sabin Vaccine Institute was awarded up to $6.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for a clinical trial to evaluate the immunogenicity and safety of lower, fractional doses of registered COVID-19 vaccines used as a booster dose. This dose optimizing trial will allow us to understand if smaller doses of COVID-19 vaccines generate similar immune responses to full doses. It will also provide key information as to whether lower doses may have fewer side effects, potentially increasing vaccine acceptance.

“This research has the potential to have the biggest impact in the places that need it the most,” said Amy Finan, CEO of the Sabin Vaccine Institute. “Just 1 in 6 people, 17.4%, have received a COVID-19 vaccine in low-income countries, compared to 72% in high income countries. There are currently sufficient global supplies of vaccine to meet demand, but that situation could change once again. The only way to end this pandemic is to ensure that everyone, everywhere has access to vaccines. That was Dr. Sabin’s goal during his lifetime, and it’s the goal now of the Sabin Vaccine Institute and this research.”

UNAIDS [to 21 May 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
20 May 2022
Helping Ukrainian refugees with HIV treatment and support in Berlin

17 May 2022
Unboxing self-esteem among transgender women in Brazil and their dreams for a dignified life

16 May 2022
Keeping LGBTI people safe in times of war

UNHCR Office of the United Nations High Commissioner for Refugees [to 21 May 2022]
Selected News Releases, Announcements
UN High Commissioner for Refugees calls on states to lift remaining pandemic-related asylum restrictions
20 May 2022
[See Week in Review above for detail]

UN High Commissioner for Refugees Filippo Grandi’s message on the International Day Against Homophobia, Transphobia and Biphobia
17 May 2022

UNICEF [to 21 May 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
IOM and UNICEF sign new strategic collaboration framework
NEW YORK, 18 May 2022 – The International Organization for Migration (IOM) and UNICEF today signed a new Strategic Collaboration Framework solidifying the organizations’ united commitment towards protecting the rights of migrant children. In 2006, UNICEF and IOM signed a Memorandum of Understanding defining the main areas of cooperation between...

Landmark meeting urges prioritization of water and sanitation to get health, climate and economic targets back on track
JAKARTA, 18 May 2022 – More than 350 participants from 57 countries gathered today in Jakarta for the opening of the Sector Ministers’ Meeting which will generate urgent prioritization of water and sanitation worldwide. Among them were 50 ministers of water, sanitation, health, environment and the economy, who met to discuss the COVID-19...

UNICEF Executive Director Catherine Russell’s remarks at UN high-level event on conflict, hunger and children with Ambassador Linda Thomas-Greenfield of the United States
NEW YORK, 17 May 2022 — "Excellencies, Colleagues, Friends. "I am honored to welcome you to UNICEF House for this critical conversation. "I want to acknowledge and thank the United States Government, and my co-host, United States Ambassador to the United Nations Linda Thomas-Greenfield, for putting children at the center of the discussion on...

World a ‘virtual tinderbox’ for catastrophic levels of severe malnutrition in children
NEW YORK, 17 May 2022 — The number of children with severe wasting was rising even before war in Ukraine threatened to plunge the world deeper into a spiralling global food crisis - and it’s getting worse, UNICEF warned in a new Child Alert. Released today, Severe wasting: An overlooked child survival emergency shows that in spite of rising levels...

Almost one billion children and adults with disabilities and older persons in need of assistive technology denied access, according to new report
GENEVA/NEW YORK, 16 May 2022 - A new report published today by WHO and UNICEF reveals that more than 2.5 billion people need one or more assistive products, such as wheelchairs, hearing aids, or apps that support communication and cognition. Yet nearly one billion of them are denied access, particularly in low- and middle-income countries, where...

Unitaid [to 21 May 2022]
https://unitaid.org/
Featured News
19 May 2022
Unitaid marks 15th anniversary, celebrates greater equity in global health

19 May 2022
UN Secretary-General commends Unitaid’s commitment to health equity and innovation in advance of 15th anniversary

19 May 2022
Former US President Bill Clinton congratulates Unitaid on 15 years of life-saving work, in advance of anniversary event

16 May 2022
Portable thermal ablation devices allow more women to access lifesaving cervical cancer prevention in countries where the majority of deaths occur

Vaccine Equity Cooperative [nee Initiative] [to 21 May 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 21 May 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 21 May 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 21 May 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
Vaccine Update for Providers
May 2022
- Announcements: Misinterpreted science, new videos and essay contest reminder
- In the journals: Underuse of convalescent plasma in treating COVID-19 led to excess deaths
- Technically speaking: The hepatitis B midlife crisis
- From the media: “With Kindness and Respect, We Can Help Others Choose to Be Vaccinated”
- On the calendar: May is Hepatitis Awareness Month
- On the bookshelf — Vaccinating Adults: A Step-by-Step Guide
- Resources: COVID conversation guide, Public Health Law News, and “For Your Health News” project

**Wellcome Trust** [to 21 May 2022]
https://wellcome.ac.uk/news
*News. Opinion, Reports*
No new digest content identified.

**The Wistar Institute** [to 21 May 2022]
*Press Releases*
No new digest content identified.

**WFPHA: World Federation of Public Health Associations** [to 21 May 2022]
https://www wfpha.org/
*Latest News - Blog*
**Older Adults’ Vaccination: Why Is Vaccination Even More Crucial for the Most Vulnerable Subgroups?**
May 19, 2022

**World Bank** [to 21 May 2022]
*Selected News, Announcements*
**World Bank Announces Planned Actions for Global Food Crisis Response**
$30 billion available for implementation to address food insecurity over next 15 months WASHINGTON, May 18, 2022—The World Bank today announced actions it plans to take as part of a comprehensive, global...
Date: May 18, 2022 Type: Press Release

**World Customs Organization – WCO** [to 21 May 2022]
http://www.wcoomd.org/
*Latest News*
17 May 2022
**WCO Members of the Asia-Pacific region share lessons learnt from COVID-19 and discuss ways to enhance preparedness to tackle disruptive events**
**World Organisation for Animal Health (OIE)**  [to 21 May 2022]
https://www.oie.int/en/  
*Press Releases, Statements*

**Egg prices on the rise: the effects of animal diseases**
*Editor's Choice*
16 May 2022

---

**WTO - World Trade Organisation**  [to 21 May 2022]
http://www.wto.org/english/news_e/news_e.htm  
*WTO News and Events [Selected]*

**WTO virtual event looks at finance and trade lessons learned from COVID-19 pandemic**
20 May 2022  
A virtual event organized by the WTO on 20 May looked at the finance and trade lessons learned from the COVID-19 pandemic over the past two years. The event was attended by representatives and government officials from WTO members and observers with responsibilities relating to the implementation and negotiation of trade, intellectual property, finance and public health issues.  
The event webpage, including access to the livestream, presentation and background materials, is available here: [WTO | Finance and Trade Lessons from the Pandemic – Looking Forward](http://www.wto.org/english/news_e/news_e.htm).

---

**ARM [Alliance for Regenerative Medicine]**  [to 21 May 2022]
*Selected Press Releases*

No new digest content identified.

---

**BIO**  [to 21 May 2022]
*Press Release*

No new digest content identified.

---

**DCVMN – Developing Country Vaccine Manufacturers Network**  [to 21 May 2022]
http://www.dcvmn.org/  
*News; Upcoming events*

No new digest content identified.

---

**ICBA – International Council of Biotechnology Associations**  [to 21 May 2022]
https://internationalbiotech.org/news/  
*News*

No new digest content identified.

---

**IFPMA**  [to 21 May 2022]
As IFPMA members, we believe that the knowledge gained from clinical trials should be used to support the development and use of innovative medicines, vaccines and other therapies, in order to develop the right treatment for the right patient. We believe that patient populations in clinical trials should be reflective of the epidemiology and demographics of those who would benefit from the therapeutic agent. To this end, we believe that diversity and inclusion in clinical trials is a matter of both equity and scientific rigor and, as such, that all individuals should have equal opportunity to participate in relevant clinical trials. The biopharmaceutical industry is committed to take affirmative steps to increase clinical trial diversity.

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 2
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 4: E249-341 Apr 2022
https://journalofethics.ama-assn.org/issue/health-equity-us-latinx-communities

Health Equity in US Latinx Communities
Latinx communities in the US include over 60 million people with a plurality of political beliefs, cultural practices, and wealth. This diversity is also expressed in population health data: some health indicators suggest advantages of Latinx community membership while other data demonstrate inequitable disease burden and maldistribution of environmental and occupational risk. Legacies of colonial conquest of the Americas persist in discrimination and marginalization today and are embodied by members of our Latinx communities.

American Journal of Infection Control
May 2022 Volume 50 Issue 5 p477-592
http://www.ajicjournal.org/current
Major Articles
The impact of COVID-19 vaccination on case fatality rates in a city in Southern Brazil
Hisrael Passarelli-Araujo, Henrique Pott-Junior, Aline M. Susuki,...Michael Aschner, Monica M.B. Paoliello, Mariana R. Urbano
Published online: February 19, 2022 p491-496

Influenza vaccination coverage among adults by nativity, race/ethnicity, citizenship, and language of the interview - United States, 2012-2013 through 2017-2018 influenza seasons
Meagan R. Chuey, Mei-Chuan Hung, Anup Srivastav,...Kimberly H. Nguyen, Walter W. Williams, Alfonso Rodriguez Lainz
Published online: September 11, 2021 p497-502
**Mask use among health care workers and feelings of safety at work pre- and post- COVID-19 vaccine**
Laura S. O'Donohue, Susan Fletcher-Gutowski, Amreetpal Sidhu, Aishwarya Verma, Tarin C. Phillips, Preeti G. Misra
Published online: November 15, 2021
p503-508

**Brief Reports**

**Racial and ethnic differences in vaccine hesitancy Among registered nurses in New Jersey: A cross-sectional survey**
Irina B. Grafova, Monika Pogorzelska-Maziarz, Mary L. Johansen, Mary Lou Manning, Suzanne Crincoli, Pamela B. de Cordova
Published online: February 11, 2022
p572-574

**American Journal of Preventive Medicine**
June 2022  Volume 62  Issue 6  p807-964
https://www.ajpmonline.org/current

**Research Articles**

**Vaccinating Veterans for COVID-19 at the U.S. Department of Veterans Affairs**
Claudia Der-Martirosian, et al.
Published online: January 31, 2022
e317-e324

**American Journal of Public Health**
May 2022  112(5)
http://ajph.aphapublications.org/toc/ajph/current

**Articles**

**COVID-19 Vaccine Uptake Among Nursing Home Staff via Statewide Policy: The Mississippi Vaccinate or Test Out Policy**
Maggie L. Syme, Natalia Gouskova and Sarah D. Berry

**American Journal of Tropical Medicine and Hygiene**
Volume 106 (2022): Issue 2 (Feb 2022)
https://www.ajtmh.org/view/journals/tpmd/106/2/tpmd.106.issue-2.xml
[Reviewed earlier]

**Annals of Internal Medicine**
May 2022  Volume 175, Issue 5
http://annals.org/aim/issue

**Original Research**

**Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data**
Chengyi Zheng, PhD, MS, Jonathan Duffy, MD, MPH, In-Lu Amy Liu, MS, Lina S. Sy, MPH, ... et al.
Pages:634–643

Reviews
Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
FREE
Anjum S. Kaka, MD, Roderick MacDonald, MS, Eric J. Linskens, BS, Lisa Langsetmo, PhD, ... et al.
Pages:701–709

Artificial Intelligence – An International Journal
Volume 306  May 2022
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 21 May 2022)
[No new digest content identified]

BMJ Global Health
May 2022 - Volume 7 - 5
https://gh.bmj.com/content/7/5
[Reviewed earlier]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 21 May 2022)
Acceptance of COVID-19 vaccine and determinant factors in the Iranian population: a web-based study
Iran had a high rate of death in several COVID 19 waves. Vaccination is a method for prevention and control of the COVID-19 pandemic. Success in controlling the pandemic is not solely dependent on the effectiv...
Authors: Shabnam Omridvar and Mojgan Firouzbakht
Citation: BMC Health Services Research 2022 22:652
Content type: Research Published on: 16 May 2022

Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru
This study aimed to estimate the economic impact of replacing the current Peruvian primary immunization scheme for infants under 1 year old with an alternative scheme with similar efficacy, based on a hexavale...
Authors: Janice Seinfeld, María Laura Rosales, Alfredo Sobrevilla and Juan Guillermo López Yescas
Testing and vaccination to reduce the impact of COVID-19 in nursing homes: an agent-based approach

Efforts to protect residents in nursing homes involve non-pharmaceutical interventions, testing, and vaccine. We sought to quantify the effect of testing and vaccine strategies on the attack rate, length of th...

Authors: José P. Gómez Vázquez, Yury E. García, Alec J. Schmidt, Beatriz Martínez-López and Miriam Nuño

Adverse effects following COVID-19 vaccination in Iran

Vaccination is a key intervention to prevent COVID-19. Many vaccines are administered globally, yet there is not much evidence regarding their safety and adverse effects. Iran also faces this challenge, especi...

Authors: Ebrahim Babaee, Ali Amirkafi, Arash Tehrani-Baníhashemi, Neda SoleimanvandíAzar, Babak Eshratí, Zahra Rampisheh, Mehran Asadi-Allábadi and Marzieh Nojomi

The assistance gaps in combating COVID-19 in Brazil: for whom, where and when vaccination occurs

Following the emergence of the COVID-19 pandemic, the number of infected Brazilian people has increased dramatically since February 2020, with Brazil being amongst the countries with the highest number of case...

Authors: Rafael da Silveira Moreira, Emilly Guaris Costa, Lucas Fernando Rodrigues dos Santos, Luiz Henrique Lélis Miranda, Raiany Rodrigues de Oliveirá, Ricardo Fusano Romão, Rodolfo Ferreira Cozer and Sarah Cavalcanti Guedes

Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey

Vaccination has been proven to be an effective approach against the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to determine the acceptance rate and factors influencing acceptance of COVID-1...
**Patient consent preferences on sharing personal health information during the COVID-19 pandemic: “the more informed we are, the more likely we are to help”**

Authors: Sarah Tosoni, Indu Voruganti, Katherine Lajkosz, Shahbano Mustafa, Anne Phillips, S. Joseph Kim, Rebecca K. S. Wong, Donald Willison, Carl Virtanen, Ann Heesters and Fei-Fei Liu

Content type: Research 20 May 2022

**An assessment of the vaccination of school-aged children in England against SARS-CoV-2**

Children and young persons are known to have a high number of close interactions, often within the school environment, which can facilitate rapid spread of infection; yet for SARS-CoV-2, it is the elderly and ... 

Authors: Matt J. Keeling and Sam E. Moore

Citation: BMC Medicine 2022 20:196

Content type: Research article Published on: 18 May 2022

**Perceptions of the Coronavirus and COVID-19 testing and vaccination in Latinx and Indigenous Mexican immigrant communities in the Eastern Coachella Valley**

A novel coronavirus, SARS-CoV-2 (known as COVID-19), spread rapidly around the world, affecting all and creating an ongoing global pandemic. Across the United States, Latinx and Indigenous populations have bee...

Authors: Daniel Gehlbach, Evelyn Vázquez, Gabriela Ortiz, Erica Li, Cintya Beltrán Sánchez, Sonia Rodríguez, María Pozar and Ann M. Cheney

Citation: BMC Public Health 2022 22:1019

Content type: Research Published on: 21 May 2022

**The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model**

High incidence of cases and deaths due to coronavirus disease 2019 (COVID-19) have been reported in prisons worldwide. This study aimed to evaluate the impact of different COVID-19 vaccination strategies in ep...

Authors: Ciara V. McCarthy, Oscar O’Mara, Edwin van Leeuwen, Mark Jit and Frank Sandmann
Public health and social measures to mitigate the health and economic impact of the COVID-19 pandemic in Turkey, Egypt, Ukraine, Kazakhstan, and Poland during 2020–2021: situational analysis
The COVID-19 pandemic had a colossal impact on human society globally. There were similarities and differences in the public health and social measures taken by countries, and comparative analysis facilitates ...
Authors: Noriko Kitamura, Kaja Abbas and Dilip Nathwani

Trinity review: integrating Registered Reports with research ethics and funding reviews
One major source of exhaustion for researchers is the redundant paperwork of three different documents—research papers, ethics review applications, and research grant applications—for the same research plan. T...
Authors: Yuki Mori, Kaito Takashima, Kohei Ueda, Kyoshiro Sasaki and Yuki Yamada

Improving research integrity: a framework for responsible science communication
Research integrity, an essential precept of scientific inquiry and discovery, comprises norms such as Rigor, Reproducibility, and Responsibility (the 3R’s). Over the past decades, numerous issues have arisen that challenge the reliability of scientific studies, including irreproducibility crises, lack of good scientific principles, and erroneous communications, which have impacted the public’s trust in science and its findings. Here, we highlight one important component of research integrity that is often overlooked in the discussion of proposals for improving research quality and promoting robust
research; one that spans from the lab bench to the dissemination of scientific work: responsible science communication.

Authors: Ilinca I. Ciubotariu and Gundula Bosch
Citation: BMC Research Notes 2022 15:177
Content type: Commentary Published on: 15 May 2022

**BMJ Evidence-Based Medicine**
April 2022 - Volume 27 - 2
https://ebm.bmj.com/content/27/2
[Reviewed earlier]

**BMJ Open**
April 2022 - Volume 12 - 4
https://bmjopen.bmj.com/content/12/4
[Reviewed earlier]

**Bulletin of the World Health Organization**
Volume 100(5); 2022 May 1
https://www.ncbi.nlm.nih.gov/pmc/issues/406286/
[Reviewed earlier]

**Cell**
May 12, 2022 Volume 185 Issue 10 p1619-1806
https://www.cell.com/cell/current
Commentary
**Precision medicine requires understanding how both sex and gender influence health**
Nina S. Stachenfeld, Carolyn M. Mazure
Progress in studying sex as a biological variable (SABV) is slow, and the influence of gendered effects of the social environment on biology is largely unknown. Yet incorporating these concepts into basic science research will enhance our understanding human health and disease. We provide steps to move this process forward.

**Child Care, Health and Development**
Volume 48, Issue 3 Pages: 359-511 May 2022
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

**Clinical Pharmacology & Therapeutics**
Volume 111, Issue 5 Pages: 973-1174 May 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]
Clinical Therapeutics
April 2022  Volume 44  Issue 4  p473-638
http://www.clinicaltherapeutics.com/current
[New issue; No digest content identified]

Clinical Trials
Volume 19 Issue 2, April 2022
https://journals.sagepub.com/toc/ctja/19/2
[Reviewed earlier]

Conflict and Health
http://www.conflicthealth.com/
[Accessed 21 May 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 116  May 2022
[Reviewed earlier]

The CRISPR Journal
Volume 5, Issue 2 / April 2022
https://www.liebertpub.com/toc/crispr/5/2
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2022 - Volume 35 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]
Developing World Bioethics
Volume 22, Issue 1  Pages: 1-62  March 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 3, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 15 - Issue 6 - December 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 23  Issue 5  4 May 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23  Issue 4  5 April 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 5—May 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 38  March 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]
Ethics & Human Research
Volume 44, Issue 3  Pages: 1-40  May–June 2022
https://onlinelibrary.wiley.com/toc/25782363/current

Reviewing research app updates • Mental illness and IRB inclusiveness
[New issue; No digest content identified]

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 21  (April 2022)
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 2, April 2022
https://academic.oup.com/eurpub/issue/32/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (4) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 3  May/June 2022
https://www.foreignaffairs.com/issues/2022/101/3
[Reviewed earlier]

Foreign Policy
Spring 2022
https://foreignpolicy.com/the-magazine/?issue_id=411130839
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 1
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 21 May 2022]
[No new digest content identified]

Global Health Action
Volume 15, Issue 1 (2022)
https://www.tandfonline.com/toc/zgha20/current?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
Vol. 10, No. 2 April 28, 2022
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 21 May 2022]
[No new digest content identified]

Global Public Health
Volume 17, Issue 5 (2022)
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 21 May 2022]
[No new digest content identified]

Health and Human Rights
Volume 23, Issue 2, December 2021
https://www.hhrjournal.org/volume-23-issue-2-december-2021/
[Reviewed earlier]

Health Economics, Policy and Law
Volume 17 - Issue 2 - April 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
Health Policy and Planning
Volume 37, Issue 5, May 2022
https://academic.oup.com/heapol/issue/37/5
[New issue; No digest content identified]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 21 May 2022]
[No new digest content identified]

Human Gene Therapy
Volume 33, Issue 9-10 / May 2022
https://www.liebertpub.com/toc/hum/33/9-10
[New issue; No digest content identified]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 1, 2022
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

Immunity
May 10, 2022 Volume 55 Issue 5 p735-924
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 21 May 2022]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 21 May 2022]
COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status

Safety data reported from the large-scale clinical trials of the coronavirus disease 2019 (COVID-19) vaccine are extremely limited in patients with decompensated cirrhosis. The vaccination campaign in this spe...
Authors: Zhujun Cao, Chenxi Zhang, Shuang Zhao, Zike Sheng, Xiaogang Xiang, Ruokun Li, Zhuping Qian, Yinling Wang, Bin Chen, Ziqiang Li, Yuhan Liu, Baoyan An, Huijuan Zhou, Wei Cai, Hui Wang, Honglian Gui...
Citation: Infectious Diseases of Poverty 2022 11:56
Content type: Research Article Published on: 16 May 2022

Could China’s journey of malaria elimination extend to Africa?

World Health Organization (WHO) certified China malaria-free on June 30, 2021, which brightens the goal of global malaria elimination efforts. China contributed its unique innovations to the global community: ... Authors: Duoquan Wang, Shan Lv, Wei Ding, Shenning Lu, Hongwei Zhang, Kokouvi Kassegne, Shang Xia, Lei Duan, Xuejiao Ma, Lulu Huang, Roly Gosling, Joshua Levens, Salim Abdulla, Mutinta Mudenda, Moses Okpeku, Kenneth Kamwi Matengu...
Citation: Infectious Diseases of Poverty 2022 11:55
Content type: Opinion Published on: 16 May 2022

International Health
Volume 14, Issue 3, May 2022
https://academic.oup.com/inthealth/issue/14/3
[Reviewed earlier]

International Human Rights Law Review
Volume 10 (2021): Issue 2 (Dec 2021)
https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol 9, No 5 (2022) May 2022
[Reviewed earlier]

International Journal of Epidemiology
Volume 51, Issue 2, April 2022
https://academic.oup.com/ije/issue

Infectious Disease
The impact of pertussis vaccine programme changes on pertussis disease burden in Manitoba, 1992–2017—an age-period-cohort analysis
Krista Wilkinson, Christiaan H Righolt, Lawrence J Elliott, Sergio Fanella, Salaheddin M Mahmud
Association Between SARS-CoV-2 Viral Load in Wastewater and Reported Cases, Hospitalizations, and Vaccinations in Milan, March 2020 to November 2021
Giovanni Nattino, PhD; Sara Castiglioni, PhD; Danilo Cereda, MD, PhD; et al.
free access
This study evaluates the association between SARS-CoV-2 load in urban wastewater and surveillance indicators of infection prevalence and severity in Milan, Italy.

Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research
The PRO Ethics Guidelines
Samantha Cruz Rivera, PhD; Olalekan Lee Aiyegbusi, PhD; Jonathan Ives, PhD; et al.
free access has active quiz has audio
These international, consensus-based, patient-reported outcomes (PRO)–specific guidelines aim to lay out the ethical considerations that researchers, research ethics committees, and funders should take into account when conducting or reviewing PRO clinical research.

COVID-19 Vaccination—Becoming Part of the New Normal
Peter Marks, MD, PhD; Janet Woodcock, MD; Robert Califf, MD
free access
In this Viewpoint, authors from the FDA discuss how COVID-19 vaccination is an integral part of establishing a new normal, now that SARS-CoV-2, the virus that causes COVID-19, will likely circulate worldwide for the foreseeable future.

COVID-19 Update May 21, 2022
These articles on COVID-19 were published across the JAMA Network in the last week.
JAMA Pediatrics
May 2022, Vol 176, No. 5, Pages 434-532
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
April 2022 - Volume 20 - Issue 4
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
May 2022 Volume 70 Issue 5 p697-838
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 74 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 2, April 2022
[Reviewed earlier]

Journal of Development Economics
Volume 156 May 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 1-2, February-April 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
April 2022 - Volume 76 - 4
https://jech.bmj.com/content/76/4
[Reviewed earlier]
**Journal of Evidence-Based Medicine**  
Volume 15, Issue 1  Pages: 1-72  March 2022  
https://onlinelibrary.wiley.com/toc/17565391/current  
[Reviewed earlier]

**Journal of Global Ethics**  
Volume 17, Issue 3, 2021  
http://www.tandfonline.com/toc/rjge20/current  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**  
Volume 33, Number 2, May 2022  
https://muse.jhu.edu/issue/47787  
Table of Contents  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**  
Volume 24, issue 3, June 2022  
https://link.springer.com/journal/10903/volumes-and-issues/24-3  
Contents  
**Willingness of a Multiethnic Immigrant Population to Donate Biospecimens for Research Purposes**  
Authors (first, second and last of 12)  
Amy Raines-Milenkov, Martha Felini, Jonathan Hughes  
Content type: Original Paper  
Open Access  
Published: 26 July 2021  
Pages: 705 - 712

**Nativity Differences in Awareness and Knowledge About HPV Infection and Vaccination Among U.S. Adults: Findings from a National Population-Based Sample**  
Authors  
Manami Bhattacharya, Serena Xiong, Annie-Laurie McRee  
Content type: Brief Communication  
Published: 28 August 2021  
Pages: 794 - 798

**Journal of Immigrant & Refugee Studies**  
Volume 20, 2022  Issue 2  
https://www.tandfonline.com/toc/wimm20/current  
Article  
**Introduction to Special Issue: Gender, Migration and Digital Communication in Asia**  
Shiori Shakuto & Brenda S. A. Yeoh  
Pages: 155-163
Abstract
In recent decades, the role of digital communication in the lives of migrants in Asia has greatly expanded, becoming integral to the decision to migrate, earning a living, and the practice of keeping in touch with left-behind families and friends. The papers in this Special Issue foreground how gender structures and practices within migrant households and the wider political economy shape migrants’ digital communications. They expand the breadth of our thinking about the interlinkages among gender, migration and digital communication from a range of new subject positions including transnational families, international students, and marginalized minorities in the region.

Journal of Infectious Diseases
Volume 225, Issue 6, 15 March 2022
https://academic.oup.com/jid/issue/225/6
EDITORIAL COMMENTARY
Editor’s Choice
Gonococcal Vaccines for Controlling Neisseria gonorrhoeae in Men Who Have Sex With Men: A Promising Game Changer
Hannah Christensen, Peter Vickerman

PERSPECTIVES
The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants
Abie Rohrig, Nir Eyal
The Journal of Infectious Diseases, Volume 225, Issue 6, 15 March 2022, Pages 934–937,
https://doi.org/10.1093/infdis/jiab488
Researchers are preparing for human challenge trials with emerging SARS-CoV-2 variants. We argue that these trials can be ethical.

Journal of Medical Ethics
May 2022 - Volume 48 - 5
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 2 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
May 2022 Volume 244 p1-262, e1-e10
http://www.jpeds.com/current
[Reviewed earlier]
Comment

Closing the global vaccine equity gap: equitably distributed manufacturing
Victor J Dzau, Celynne A Balatbat, Anaeze C Offodile II
**Articles**

**Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses**

WHO Solidarity Trial Consortium

*Open Access*

**Background**

The Solidarity trial among COVID-19 inpatients has previously reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and interferon (IFN)-β1a were discontinued for futility but randomisation to remdesivir continued. Here, we report the final results of Solidarity and meta-analyses of mortality in all relevant trials to date.

**Interpretation**

Remdesivir has no significant effect on patients with COVID-19 who are already being ventilated. Among other hospitalised patients, it has a small effect against death or progression to ventilation (or both).

**Series**

**Political Science and Health**

**Framing and the formation of global health priorities**

Jeremy Shiffman, Yusra Ribhi Shawar

**Summary**

Health issues vary in the amount of attention and resources they receive from global health organisations and national governments. How issues are framed could shape differences in levels of priority. We reviewed scholarship on global health policy making to examine the role of framing in shaping global health priorities. The review provides evidence of the influence of three framing processes—securitisation, moralisation, and technification. Securitisation refers to an issue's framing as an existential threat, moralisation as an ethical imperative, and technification as a wise investment that science can solve. These framing processes concern more than how issues are portrayed publicly. They are socio-political processes, characterised by contestation among actors in civil society, government, international organisations, foundations, and research institutions. These actors deploy various forms of power to advance particular frames as a means of securing attention and resources for the issues that concern them. The ascription of an issue as a security concern, an ethical imperative, or a wise investment is historically contingent: it is not inevitable that any given issue will be framed in one or more of these ways. A health issue's inherent characteristics—such as the lethality of a pathogen that causes it—also shape these ascriptions, but do not fully determine them. Although commonly facing resistance, global health elites often determine which frames prevail, raising questions about the legitimacy of priority-setting processes. We draw on the review to offer ideas on how to make these processes fairer than they are at present, including a call for democratic representation even as necessary space is preserved for elite expertise.

**The Lancet Child & Adolescent Health**

May 2022 Volume 6 Number 5 p279-352, e16-e19

https://www.thelancet.com/journals/lanchi/issue/current

[Reviewed earlier]

**Lancet Digital Health**
Lancet Global Health
Jun 2022 Volume 10 Number 6 e773-e926
https://www.thelancet.com/journals/langlo/issue/current
Articles
**Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study**
Alejandro Jara, et al.

Lancet Infectious Diseases
May 2022 Volume 22 Number 5 p563-742, e128-e158
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
May 2022 Volume 7 Number 5 e391-e484
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
May 2022 Volume 10 Number 5 p421-524, e44-e50
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 26, issue 5, May 2022
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 42 Issue 4, May 2022
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
*A Multidisciplinary Journal of Population Health and Health Policy*
Volume 100, Issue 1 Pages: 1-313 March 2022
https://onlinelibrary.wiley.com/toc/14680009/current
**Nature**
Volume 605 Issue 7910, 19 May 2022
https://www.nature.com/nature/volumes/605/issues/7910

*Comment | 12 May 2022*

**Want to prevent pandemics? Stop spillovers**
Decision-makers discussing landmark agreements on health and biodiversity must include four actions to reduce the risk of animals and people exchanging viruses.
Neil M. Vora, Lee Hannah, Aaron S. Bernstein

**Nature Biotechnology**
Volume 40 Issue 5, May 2022
https://www.nature.com/nbt/volumes/40/issues/5

*Editorial | 09 May 2022*

**Gene therapy at the crossroads**
Two upcoming regulatory decisions represent a tipping point for commercial gene therapy, with implications for work on existing viral vectors and the pursuit of new ones.

**Nature Communications**
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 21 May 2022)
[No new digest content identified]

**Nature Genetics**
Volume 54 Issue 5, May 2022
https://www.nature.com/ng/volumes/54/issues/4

*Comment | 05 May 2022*

**Polygenic risk scores for CARDINAL study**
The Cardiometabolic Disorders in African-Ancestry Populations (CARDINAL) study site is a well-powered, first-of-its-kind resource for developing, refining and validating methods for research into polygenic risk scores that accounts for local ancestry, to improve risk prediction in diverse populations.
Clement A. Adebamowo, Adebowale Adeyemo, Sally N. Adebamowo

*Comment | 09 May 2022*

**Promoting the genomic revolution in Africa through the Nigerian 100K Genome Project**
To leverage the genetic diversity in Nigeria, we established the Non-Communicable Diseases Genetic Heritage Study (NCD-GHS) consortium to help produce a comprehensive catalog of human genetic variation in Nigeria and assess the burden and etiological characteristics of non-communicable diseases in 100,000 adults in Nigeria.
Segun Fatumo, Aminu Yakubu, Abasi Ene-Obong

**Nature Human Behaviour**
Nature Medicine
Volume 28 Issue 5, May 2022
https://www.nature.com/nm/volumes/28/issues/5
Editorial | 18 May 2022
Walking the tightrope between data sharing and data protection
With the increase in genomic data available and the advent of new technology for mining it, balancing the needs for data sharing and data protection becomes more challenging. Different disciplines must come together to find new solutions.

Comment | 09 May 2022
The distinct impacts of race and genetic ancestry on health
Genetic ancestry affects human health, but this is distinct from the impact of race, a social construct that has its foundations in systemic racism. These terms need to be better defined and understood in medical research to achieve health equity.
Timothy R. Rebbeck, Brandon Mahal, Kosj Yamoah

Comment | 05 April 2022
An equitable roadmap for ending the COVID-19 pandemic
Many governments are rolling back restrictions, but the pandemic will end only with a renewed focus on equitable distribution of vaccines and therapeutics, responsive public health plans, and policies to protect the vulnerable.
Mitsuru Mukaigawara, Ines Hassan, Devi Sridhar

Brief Communication | 24 February 2022 | Open Access
Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
A multi-scale model using population-level transmission and individual-level vaccination data suggests that vaccine dose fractionation could be a cost-effective strategy for mitigating the COVID-19 pandemic in India.
Zhanwei Du, Lin Wang, Benjamin J. Cowling

Article | 03 March 2022 | Open Access
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
A third dose of the COVID-19 vaccine mRNA-1273 is safe and boosts SARS-CoV-2 neutralizing antibody titers almost two-fold higher than the peak levels observed after completion of a two-dose series, highlighting the potential clinical benefit of a booster dose.
Laurence Chu, Keith Vrbicky, Roderick McPhee

Article | 21 February 2022 | Open Access
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
A test-negative case–control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is
reduced against infection with the Omicron SARS-CoV-2 variant in comparison to Delta, but that efficacy against hospitalization remained high for both variants.
Hung Fu Tseng, Bradley K. Ackerson, Lei Qian

Article | 14 February 2022 | Open Access
**Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines**
A large study in the United Kingdom shows that virus-specific antibody levels associated with at least 67% protection against SARS-CoV-2 Delta variant infection last longer after two doses of BNT162b2 vaccine than after two doses of ChAdOx1 vaccine in previously uninfected individuals.
Jia Wei, Koen B. Pouwels, Chris Cunningham

**Nature Reviews Genetics**
Volume 23 Issue 5, May 2022
https://www.nature.com/nrg/volumes/23/issues/5
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 22 Issue 5, May 2022
https://www.nature.com/nri/volumes/22/issues/5
[Reviewed earlier]

**Nature Reviews Drug Discovery**
Volume 21 Issue 5, May 2022
https://www.nature.com/nrd/volumes/21/issues/5
[Reviewed earlier]

**New England Journal of Medicine**
May 19, 2022 Vol. 386 No. 20
https://www.nejm.org/toc/nejm/medical-journal
Original Articles
**BNT162b2 Protection against the Omicron Variant in Children and Adolescents**
A.M. Price and Others

**Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine**
E.D. Moreira, , and Others

**npj Vaccines**
https://www.nature.com/npjvaccines/
[Accessed 21 May 2022]
Article
[No new digest content identified]
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
Research Article | published 17 May 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003991
Research Article
The health impacts of the COVID-19 pandemic on adults who experience imprisonment globally: A mixed methods systematic review
Hannah Kim, Emily Hughes, Alice Cavanagh, Emily Norris, Angela Gao, Susan J. Bondy, Katherine E. McLeod, Tharsan Kanagalingam, Fiona G. Kouyoumdjian
Research Article | published 20 May 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0268866

What drives willingness to receive a new vaccine that prevents an emerging infectious disease? A discrete choice experiment among university students in Uganda
Kimberly E. Bonner, Henry Ssekyanzi, Jonathan Sicsic, Judith E. Mueller, Traci Toomey, Angela K. Ulrich, Keith J. Horvath, James D. Neaton, Cecily Banura, Nicole E. Basta
Research Article | published 19 May 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0268063

A randomized controlled trial of a video intervention shows evidence of increasing COVID-19 vaccination intention
Leah S. Witus, Erik Larson
Research Article | published 19 May 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0267580

COVID-19 vaccine acceptance among health care workers in Africa: A systematic review and meta-analysis
Martin Ackah, Louise Ameyaw, Mohammed Gazali Salifu, Delali Pearl Afi Asubonteng, Cynthia Osei Yeboah, Eugene Norkotey Annor, Eunice Abena Kwartemaa Ankapong, Hosea Boakye
Research Article | published 18 May 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0268711

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 21 May 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
May 17, 2022 vol. 119 no. 20
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Issue 3 - June 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[New issue; No digest content identified]
Preventive Medicine
Volume 158  May 2022
[Reviewed earlier]

Proceedings of the Royal Society B
25 May 2022  Volume 289  Issue 1975
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 206  Pages e1-e2, 1-102 (May 2022)
[Reviewed earlier]

Public Health Ethics
Volume 14, Issue 3, November 2021
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 3, May/June 2022
https://journals.sagepub.com/toc/phrg/137/3
[New issue; No digest content identified]

Qualitative Health Research
Volume 32 Issue 4, March 2022
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 18 Issue 2, April 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 21 May 2022]
[No new digest content identified]
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 42, Issue 4  Pages: 657-911  April 2022
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 21 May 2022]
[Reviewed earlier]

Science
Volume 376| Issue 6595| 20 May 2022
https://www.science.org/toc/science/current
[New issue; No digest content identified]

Science and Engineering Ethics
Volume 28, issue 2, April 2022
[Reviewed earlier]

Science Translational Medicine
Volume 14| Issue 645| 18 May 2022
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Social Science & Medicine
Volume 298  April 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 21 May 2022]
[No new digest content identified]
Theoretical Medicine and Bioethics
Volume 43, issue 1, February 2022
https://link.springer.com/journal/11017/volumes-and-issues/43-1
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 46  March–April 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 5  Pages: i-iv, 467-543  May 2022
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 40, Issue 20  Pages 2819-2894 (3 May 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/20
Discussion  Full text access
Supporting immunization programs to address COVID-19 vaccine hesitancy:
Recommendations for national and community-based stakeholders
Katelyn Wells, Kelly L. Moore, Robert Bednarczyk
Pages 2819-2822

Short communication  Abstract only
Rayleen M. Lewis, Lauri E. Markowitz
Pages 2828-2832

Research article  Full text access
Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021
Chao Ma, Weiwei Sun, Tingting Tang, Manhong Jia, ... Zhijie An
Pages 2869-2874

Research article  Open access
Nepal measles outbreak response immunization during COVID-19: A risk-based intervention strategy
Anindya Sekhar Bose, Pasang Rai, Binod Prasad Gupta, Rahul Pradhan, ... Jhalak Sharma Gautam
Pages 2884-2893
THEMED SECTION: COVID-19

Quantifying the Effect of Public Activity Intervention Policies on COVID-19 Pandemic Containment Using Epidemiologic Data From 145 Countries
Jichao Sun, Yefeng Zheng, Wenhua Liang,...Man Tat Alexander Ng, Jianxing He, Nanshan Zhong
Published online: December 07, 2021
p699-708

Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations
Jamie Elvidge, Ashley Summerfield, David Nicholls, Dalia Dawoud
Published online: February 16, 2022
p773-784
Open Access

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Neonatal outcomes and indirect consequences following maternal SARS-CoV-2 infection in pregnancy: A systematic review
Sarah Sturrock, Shohaib Ali, Christopher Gale, Cheryl Battersby, Kirsty Le Doare
medRxiv 2022.05.20.22275313; doi: https://doi.org/10.1101/2022.05.20.22275313

BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children
Yannic C Bartsch, Jessica W Chen, Jaewon Kang, Madeline D Burns, Kerri J St.Denis, Maegan L Sheehan, Jameson P Davis, Alejandro B Balazs, Lael M Yonker, Galit Alter
medRxiv 2022.05.18.22275283; doi: https://doi.org/10.1101/2022.05.18.22275283

Estimating Vaccine-Preventable COVID-19 Deaths Under Counterfactual Vaccination Scenarios in the United States
LEGAL AGE OF CONSENT FOR HIV TESTING AMONG ADOLESCENTS IN SUB SAHARAN AFRICA, A SYSTEMATIC REVIEW
Getrud Joseph Mollel, Andrew Katende, Maryam Shahmanesh
medRxiv 2022.05.17.22275222; doi: https://doi.org/10.1101/2022.05.17.22275222

Parents’ intention to vaccinate their child for COVID-19: a cross-sectional survey (CoVAccS - wave 3)
Louise E Smith, Susan M Sherman, Julius Sim, Richard Amlot, Megan Cutts, Hannah Dasch, Nick Sevdalis, G James Rubin
medRxiv 2022.05.20.22275350; doi: https://doi.org/10.1101/2022.05.20.22275350

Covid-19 Vaccine Acceptance Among People Incarcerated in Connecticut State Jails
Margaret Lind, Byron S Kennedy, Murilo Dorion Nieto, Amy J Houde, Peri Sosensky, Ryan Borg, Derek A.T. Cummings, Albert Ko, Robert P Richeson
medRxiv 2022.05.19.22275339; doi: https://doi.org/10.1101/2022.05.19.22275339

How Should COVID-19 Vaccines be Distributed between the Global North and South? A Discrete Choice Experiment in Six European Countries
JI Steinert, H Sternberg, GA Veltri, T Büthe
medRxiv 2022.05.19.22275055; doi: https://doi.org/10.1101/2022.05.19.22275055

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults in the United States
Katherine E. Mues, Brenna Kirk, Deesha A. Patel, Alice Gelman, Scott Chavers, Carla Talarico, Daina B. Esposito, David Martin, James Mansi, Xing Chen, Nicolle M. Gatto, Nicolas Van de Velde
medRxiv 2022.05.13.22274960; doi: https://doi.org/10.1101/2022.05.13.22274960

10.4 Million Children Affected by COVID-19-associated Orphanhood and Caregiver Death: An Imperative for Action
Susan Hillis, Joel-Pascal Ntwali N’konzi, William Msembali, Lucie Cluver, Andrés Villaveces, Seth Flaxman, H. Juliette T. Unwin
medRxiv 2022.05.08.22274788; doi: https://doi.org/10.1101/2022.05.08.22274788 Revision

United States’ political climates and the spread of SARS-2-COVID-19 during 2020
Felicia Pratto, Andrew Cortopassi, Natasza Marrouch
medRxiv 2022.05.16.22275162; doi: https://doi.org/10.1101/2022.05.16.22275162

Mapping publication outputs, collaboration networks, research hotspots, and most cited articles in systematic reviews and meta-analyses of medicine and health sciences in Ethiopia: analyses of 20 years of scientific data
Tesfa Dejenie Habtewold, Nigussie Tadesse Sharew, Aklilu Endalamaw, Henok Mulugeta, Getenet Dessie, Nigus G. Asefa, Getachew Mulu Kassa, Wubet Alebachew Bayih, Mulugeta Molla Birhanu, Balewgiye Sileshi Tegegne, Andreas A. Tefera, Adera Kenay Tura, Sisay Mulugeta Alemu
medRxiv 2022.02.24.22271416; doi: https://doi.org/10.1101/2022.02.24.22271416 Revision
The effects on clinical trial activity of direct funding and taxation policy interventions made by government: a systematic review
Sam Crosby, Esther Rajadurai, Stephen Jan, Bruce Neal, Richard Holden
medRxiv 2022.05.13.22275062; doi: https://doi.org/10.1101/2022.05.13.22275062

Social clustering of unvaccinated children: measles-mumps-rubella vaccination coverage in schools in the Netherlands
Don Klinkenberg, Albert Jan van Hoek, Irene Veldhuijzen, Susan Hahné, Jacco Wallinga
medRxiv 2022.05.12.22273875; doi: https://doi.org/10.1101/2022.05.12.22273875

Wellcome Open Research [to 21 May 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 21 May 2022]

Research Article metrics AWAITING PEER REVIEW
Assessing the impact of COVID-19 on STEM (science, technology, engineering, mathematics) researchers in India [version 1; peer review: awaiting peer review]
Nikita Mehta, Vedika Inamdar, Arathy Puthillam, Shivani Chunekar, Hansika Kapoor, Anirudh Tagat, Deepa Subramanyam
Peer Reviewers Invited
Funder
The Wellcome Trust DBT India Alliance
PUBLISHED 20 May 2022

Study Protocol metrics AWAITING PEER REVIEW
The safety and immunogenicity of a combined pertussis containing vaccine Tdap for HIV infected pregnant women and their newborns (WoMANPOWER) – A study protocol for a randomized clinical trial [version 1; peer review: awaiting peer review]
Eve Nakabembe, Bahaa Abu-Rayya, Mary Kyohere, Valerie Tusubira, Alexander Amone, Lydia Nakibuuka, Madeleine Cochet, Annettee Nakimuli, Merryn Voysey, Andrew Gorringe, Paul T. Heath, Philippa Musoke, Nick Andrews, Musa Sekikubo, Manish Sadarangani, Kirsty Le Doare
Peer Reviewers Invited
Funders
Wellcome
National Institute for Health Research
Department for International Development
Medical Research Council
Canadian Institutes of Health Research
PUBLISHED 17 May 2022

* * * * *

Think Tanks

Brookings [to 21 May 2022]
Accessed 21 May 2022

**Center for Global Development**  [to 21 May 2022]
https://www.cgdev.org/
Research [Selected]
[No new digest content identified]

**Chatham House**  [to 21 May 2022]
https://www.chathamhouse.org/
Accessed 21 May 2022
[No new digest content identified]

**CSIS**  [to 21 May 2022]
https://www.csis.org/
Accessed 21 May 2022
Podcast Episode

**North Korea: A Covid-19 Disaster Unlike Any Other**
May 20, 2022 | By J. Stephen Morrison, H. Andrew Schwartz, Victor Cha

Transcript

**Book Event: Pfizer CEO Albert Bourla's "Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible"**
May 19, 2022

was thinking that I did the vaccine. Actually, I was part of ... produce what they did with the vaccine. So it is – we have plenty ... made a decision early in the vaccine development process not to ...

**Kaiser Family Foundation**
https://www.kff.org/search/?post_type=press-release
Accessed 21 May 2022

May 16, 2022 News Release

**COVID-19 Vaccination Rates Among Nursing Home Staff Have Risen by 25 Percentage Points Since the Biden Administration Announced a Vaccination Mandate for Health Care Workers Last Year**

In a new analysis, KFF researchers find that COVID-19 vaccination rates among nursing home staff increased by 25 percentage points nationally (63% to 88%) from when the Biden administration announced the vaccine mandate for health care workers in August 2021 to after vaccination deadlines passed in March 2022. Researchers analyzed...

**ODI [Overseas Development Institute]**  [to 21 May 2022]
**Publications**

**Accessed** 21 May 2022

[No new digest content identified]

---

**Rand** [to 21 May 2022]

https://www.rand.org/pubs.html

*Reports, Selected Journal Articles*

*Journal Article*

**Protecting the Mental and Physical Well-Being of Frontline Health Care Workers During COVID-19: Study Protocol of a Cluster Randomized Controlled Trial**

The COVID-19 pandemic has placed health care workers at unprecedented risk of stress, burnout, and moral injury. This paper describes the design of an ongoing cluster randomized controlled trial to compare the effectiveness of Stress First Aid (SFA) to Usual Care (UC) in protecting the well-being of frontline health care workers.

May 17, 2022

Lu Dong, Lisa S. Meredith, Carrie M. Farmer, Sangeeta C. Ahluwalia, Peggy G. Chen, Kathryn E. Bouskill, Bing Han, Nabeel Qureshi, Sarah Dalton, Patricia J. Watson, Jonathan N. Tobin, Andrea Cassells, Courtney A. Gidengil

---

**Urban Institute** [to 21 May 2022]

https://www.urban.org/publications

*Research Publications*

[No new digest content identified]

---

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

::::::::::

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller Foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.